Centre for Society and Genomics 2008-2012 : Business Plan by Nelis, A.P. & Zwart, H.A.E.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The version of the following full text has not yet been defined or was untraceable and may
differ from the publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/113040
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
  
 
 
 
 
Centre for Society and Genomics 
2008 – 2012 
 
Business Plan 
 
 
 
 
 
  
 
 
Dr. A.P. Nelis  
Prof. Dr. H.A.E. Zwart 
 
Nijmegen, April 2, 2007 
CSG Societal Research & Public Interaction 2008-2012  
Foreword 
 
This document presents the agenda of the Centre for Society and Genomics (CSG) for the period 2008-
2012. During the past 2, 5 years, CSG has developed a national and international programme for research 
and public interaction concerning the relationship between society and genomics. The plans for 2008-2012 
not only include the activities of CSG as such. Rather, they involve the societal research projects and 
communication and education activities of all Genomics Centres funded by NGI:  
 
Centre for BioSystems Genomics (CBSG)  
Centre for Medical Systems Biology (CMSB) 
Kluyver Centre for Genomics of Industrial Fermentation (Kluyver Centre) 
Cancer Genomics Centre (CGC) 
Ecogenomics Consortium  
Netherlands Metabolomics Centre (NMC). 
Netherlands Consortium for Healthy Ageing (NCHA) 
Nutrigenomics Consortium 
Celiac Disease Consortium (CDC) 
VIRGO Consortium 
Forensic Genetics Consortium Netherlands (FGCN) 
Netherlands Proteomics Centre (NPC)  
Netherlands Bioinformatics Centre (NBIC)  
Netherlands Toxicogenomics Centre (NTC) 
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4 Executive summary 
Genomics is here to stay. In the years to come, society will increasingly be confronted with genomics 
applications. It is the ambition of the Centre for Society and Genomics (CSG) to improve the conditions 
for embedding genomics in society. This calls for: 
• Good governance: embedding genomics applications in society in a transparent and well-informed 
manner and in a way that takes into account the needs and interests of (different groups of) 
citizens and institutions.  
• Alignment of the opportunities that genomics technologies offer with the expectations and needs 
of society. Hence, a socially robust genomics agenda.  
• Education and communication about genomics to ensure that publics and professionals are 
knowledgeable and well-informed in order to critically assess current and future applications. 
These three objectives form the basis of our plan. They are represented in three programmes, and each of 
these programmes covers two major themes.  
 
1.1 Changing practices and policies I.   Genomics Applications 
1.2 Identity and Behaviour 
2.1 Transformation of knowledge production II.  Genomics Agenda  
2.2 Knowledge and benefits  
3.1 New forms of public interaction III. Genomics Education & 
Communication  3.2 Education and expertise  
Since 2004, the Centre for Society and Genomics (CSG) has developed an interactive programme for 
studying and improving the relationship between genomics and society. This programme includes 22 
research projects; a series of education programmes for bachelor, master and postgraduate students; a 
public website and mobile DNA laboratories for upper secondary students; and numerous societal 
discussions, dialogue and debates. The current plan continues, but also expands and consolidates this 
programme. Governing the societal embedding of genomics calls for an on-going and focussed effort.  
Following the advice of our international mid-term review committee, we will further develop our 
interactive approach. Our plan will continue to combine research with societal interaction (e.g. public 
communication, education, public debate and policy briefings). Thus, most of the research projects 
described in this plan focus on societal interaction (what can we learn from such activities and how can we 
improve them?), but the reverse is also true: the activities that we organise function as test-beds or input 
for our research. Therefore, in the context of our three programmes, research and societal interaction are 
presented in a comprehensive way.  
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This is an ambitious plan. It includes not only the work of the centre at Radboud University Nijmegen, but 
also the societal research and public communication activities of the Genomics Centres funded by NGI. 
Moreover, CSG works with a network of prominent ELSA-genomics researchers from other universities.1 
These three parties – CSG Nijmegen, the Genomics Centres and ELSA-genomics researchers – each 
conduct a significant part of our plan. Our interactive approach – combining research with interaction – is 
the basis for all research groups participating in this plan.  
The collaboration of the Centre in Nijmegen with the ELSA-network and with the Genomics 
Centres is also built into the management structure of CSG. While the day-to-day management and 
programme management will be based at Radboud University Nijmegen, the six Principal investigators – 
who are responsible for developing our six major themes and who, together with the programme 
managers, form the programme committee – represent prominent research groups and/or Centres of 
Excellence. 
The deliverables of this programme: 20 PhD thesis’s, 250 scientific articles, 50 articles in popular 
magazines, 55 public discussions, debates and dialogues; 120,000 hits annually at watisgenomics.nl; 
200.000 visitors of one of the DNA mobile labs; the development of a virtual lab and a genomics test-lab 
for science centres; 2 large-scale patient information days; a genomics science festival; several modules 
for health professionals and much more. Ultimately, the programme aims to strengthen the governance of 
genomics; improve the quality of public debate (so as to prevent unnecessary adverse affects) and to 
further people’s knowledge about genomics as well as their ability to provide a critical assessment of 
genomics applications.  
Genomics is here to stay, and so is CSG. In the future, however, genomics will migrate to novel 
emerging fields and become so firmly embedded that it no longer will be viewed as a separate research 
domain. After 2012, CSG will continue its programme, but no doubt it will do so in a different world in 
which both genomics and society have changed. Current investments will allow us to broaden our scope 
and to become relevant for an increasing number of partners in the life-sciences and a broad range of 
(international) funding schemes. The plan for the coming five years ensures that CSG by that time is well 
positioned, locally, nationally as well as internationally, to further develop its methods and themes in the 
context of research, education, policy and debate. 
 
                                                 
1 ELSA stands for Ethical, Legal and Social Aspects.  
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5 Societal impact, mission and ambition  
On April 2, 2020 Heather is born. Her parents are invited to subject their daughter to a Heel-prick 
procedure. Aided by an interactive computer programme that processes their family histories, they are 
requested to make their own personal selection from a list of 120 conditions. Working through a second 
interactive computer program, explaining the benefits and risks of all available tests, they agree (and sign 
informed consent) to subject Heather to genetic tests that provide risk information for 22 conditions. Not 
all of these are treatable, but for most of them preventive strategies are available. Some of these 
conditions will cause undesirable behaviour rather than physical complaints. On the basis of these tests, 
Heather’s parents are informed about their child’s susceptibility to heart-disease, Alzheimer, depression, 
ADD and several forms of cancer. Also an estimate of Heather’s life-span is disclosed. Subsequently they 
are referred to a life-style counsellor to obtain a personalised scheme for medication, diet and life-style 
advice. They are also invited to participate in counselling sessions with other couples. Finally they agree 
that the genetic data (in an anonymous format) may be used for further biomedical and epidemiological 
research (to be confirmed by Heather herself when she is 18 years old). 
  
The above scenario depicts a world in which genomics has become an integral part of our societies and of 
the lives of individual men and women. Similar scenarios can be developed for bio-energy or plant 
genomics. In 2020, we may fill our cars with bio-fuels or spray our gardens with metagenomic solutions in 
order to improve soil quality. How will such scenarios affect global deforestisation or the amount of food 
that is available for consumption? Scenarios about the future uses of genomics science and technology 
trigger important questions. Are they realistic? Is it desirable for these scenarios to become reality? If so, 
under what conditions? How to prepare society (citizens, scientists, policy makers) for these futures? 
These are the issues our plan aims to address.  
During the next five years, more and more genomics applications will find their way into society. 
This raises a broad range of questions concerning the ways in which genomics research and applications 
are to be meaningfully embedded. These questions can be organised under three headings. First of all, 
what are the implications and applications of genomics in various practices? How will genomics affect 
society and vice versa? Secondly, how will the agenda of genomics evolve in the near future? To what 
extent can this agenda be directed towards societal demands and “societal tasks”2? Finally, how can 
education and communication empower citizens, students, policy-makers and researchers to assess 
genomics developments and applications? Investments in genomics will be wasted if we fail to address 
these questions in a timely and well-informed manner. 
                                                 
2 Ministry of Health, Welfare and Sports (VWS) Social Tasks for Public health and Health Care. The Hague, 2006.  
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This plan concerns the Ethical, Legal and Social Aspects (ELSA) of Genomics, that is: the interrelatedness 
of genomics and society (Gaskell & Bauer 2006, Nelis et al 2006). It combines scientific research with 
societal interactions (e.g. education, information, communication and policy engagement). It is an 
indispensable part of NGI’s overall Strategic Plan because it: 
 
1. enables timely reflection on the future promises of genomics 
2. helps to shape the agenda of genomics in such a way that genomics will be relevant for society in 
general and for a number of societal groups and stakeholders in particular. 
3. avoids polarised debates.  
4. builds on and provides mass, focus and greater visibility to the achievements of ELSA genomics in 
the Netherlands. 
 
There is no simple causal relationship between publications and public interactions concerning genomics 
on the one hand and the style or atmosphere of the public debate on the other. However, the work of social 
science and humanities scholars has contributed to the open-minded and balanced nature of the 
discussions during the past five years, in comparison to the debate over (for example) GM-food in the 
1990s. Instead of asking the question “How will we profit from societal research?” we should rather ask 
“What damage will be done when we do not invest in studying and improving the interaction between 
genomics and society?”  
 
Mission and Scope of the programme 
This programme bridges the gap between the potentials of technological innovation on the one hand and 
societal demands and expectations on the other. It attunes the promises of a healthier, wealthier and more 
sustainable world to the needs of our societies. 
The innovation potential of genomics that is studied in this programme is directly linked to the 
topics and themes of the research programmes of NGI’s Genomics Centres. Our programme thus focuses 
on topics such as cancer, target crops, proteomics, forensics, bioinformatics, multifactorical diseases, 
fermentation, ageing, nutrigenomics, toxicogenomics, metabolomics, infectious diseases, Celiac disease 
and ecogenomics. For each of these topics we will ask the question “What are the societal issues at stake?” 
and organise timely (public) discussion and dialogue. In this way, citizens are invited and empowered to 
reflect on short-term and future applications.  
Although our activities focus on the topics of the Genomics Centres, they are not “technology-
driven”. Rather, our strategy is to approach these issues from “both sides”. It is the aim of our plan to 
bring genomics research agendas and societal agendas closer together. Issues such as the assumptions 
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underlying genomics research or the ways in which genomics is organised in public-private constellations, 
for example, are explicitly addressed. Also so-called “macro” questions will be dealt with, questions that 
go beyond the interest of individual Centres or national boundaries. To what extent does genomics enable 
a fair sharing of benefits and natural resources? To what extent does it contribute to the alleviation of 
poverty? How can it contribute to the elimination of rare diseases?  
Our programme aims to make the development of genomics science and technology more 
“socially robust” (Nowotny 2003) and to explore and further the conditions for the embedding of 
genomics in society. We borrow the term “embedding” from science and innovation studies. It refers to 
aligning societal demands, innovative capacities and the rules, regulations and institutions that govern 
these innovations.  
 
Our mission is to understand and improve the conditions that determine the societal embedding of 
genomics. 
  
First of all, it is our objective to improve the conditions for societal embedding: a dynamic process in 
which society and societal actors play a decisive role. These ambitions call for substantial research efforts, 
but always in combination with activities in the realm of public and stakeholder interaction. To improve 
the conditions for societal embedding, it is important to understand and elucidate the ways in which 
genomics research programs are evolving, in close interaction with their social and cultural environments. 
Beside, it is important to critically assess the conditions for societal embedding. Based on a thorough 
analysis of past experiences and of the dynamics of the interaction between science, technology and 
society, this programme aims to anticipate the (future) impacts of genomics for society.  
 Who is the “we” in this report? “We” refers to the Centre based at Radboud University Nijmegen. 
Yet, CSG is a network organisation. Our plan includes all the societal research and public interaction of 
the Genomics Centres of NGI. Moreover, part of our plan is carried out by ELSA groups and experts at 
other universities in the Netherlands. These three actors (CSG Nijmegen, Genomics Centres, the ELSA 
Network) all conduct a significant part of the activities described in this plan. The management of this 
plan is based in Nijmegen, but the Programme Committee includes representatives from all three actors. 
This places us in a unique position to build a strong network that combines coherence and focus with 
national visibility and outreach and will ensure conditions for sustaining our activities in the future. 
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Aims and Ambitions  
In 2012 we want to have achieved: 
1) That genomics governance is well organised. This requires: 
a) That citizens, genomics researchers, ELSA researchers, NGO’s and industry have more expertise 
about the societal aspects of genomics.  
b) That dialogue with the public on potentially controversial applications of genomics takes place at 
an early stage and in an open-minded and well-informed way.  
2) That a durable ELSA genomics knowledge network is established.  
 
Ad 1 Genomics science and technology will in principle affect us all. Questions concerning the 
application and use of genomics as well as the (future) agenda of genomics, therefore, are (or rather, 
should be) a matter of concern for all. We therefore need “good governance” of genomics. This implies 
among other things that different parties are being heard and that the decision-making process is 
transparent, sensitive and interactive. In 2012, professionals, scientists, citizens (including minority 
groups) and public interest groups must have a say in the shaping of the agenda of genomics science and 
technology.  
More expertise means more knowledge and information about genomics as well as the ability to 
critically assess this information. A significant part of our programme therefore will be dedicated to 
capacity building. In 2012, more than 120,000 school children have used one of the mobile DNA labs, 
more than 200,000 people will visit watisgenomics.nl every year, and more than 20,000 people have been 
involved in “live” or virtual debates on genomics. A significant part of the general population will know 
what genomics science and technology is about and must be aware of its societal impact. 
The committee responsible for the Dutch public debate on GM food (Eten en Genen), concluded 
that the government should develop better methods to improve timely public dialogue concerning the life 
sciences.3 We take this recommendation seriously and aim to improve the quality of the public debate on 
genomics. In particular, we will organise dialogue earlier, including more people, using new ways for 
reaching out to the public. In 2012, the concept of genomics and its implications will be a well-known 
topic of public discussion and dialogue.  
  
                                                 
3 “De overheid moet betere methoden ontwikkelen om in een vroeg stadium in dialoog te kunnen treden met het brede publiek 
over de mogelijke toepassingen van de beschikbare kennis op het gebied van de levenswetenschappen”. Eten & Genen, een 
publiek debat over biotechnologie en voedsel, 2002, p.7. 
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Ad 2. The aim of this programme is not only to develop and conduct activities over the next five years, but 
to use them in order to firmly embed this type of expertise and work, by building a durable network of 
ELSA experts that will continue to exist after 2012. Our approach to combine research and societal 
interaction will be widely used and embedded both within CSG and the Genomics Centres.  
  
The Shoulders on which we stand  
This programme does not start from scratch. Rather, it integrates various initiatives and continues the 
development of research and interaction activities of a number of different actors. First of all, we benefit 
from the efforts and results of the NWO-programme “Societal Component of Genomics”. This 
programme has shown that in the past few years, genomics has manifested itself more and more in all 
layers of society: politics, care, science, industry, arts, education etc. As this process will continue, “real-
time” reflection on the societal implications of genomics is needed.  
Secondly, four Genomics Centres have developed a societal programme accompanying or 
integrated within their genomics research. CBSG, CMSB, Kluyver Centre and CGC have conducted 
ELSA-research and communication projects that included stakeholders, patients, professionals and 
genomics scientists. These programmes have been positively assessed by the different international 
scientific juries of the Centres.  
Thirdly, CSG itself has developed a substantial programme for ELSA-research and public 
interactions. The 22 research projects conducted by CSG aim to understand the dynamics of genomics 
research and of public interactions such as policy engagement, capacity building and public dialogue. 
Besides, CSG organizes a number of public interaction activities, such as a public website; theatre plays; 
discussions; film debates etc. These activities are at the same time objects of research. Many of these 
activities – watisgenomics.nl, DNA-labs and Imagine – have been developed together with the Genomics 
Centres of NGI. 
 
ELSA genomics: the next step 
The programme 2008-2012 will use the quality and experiences of the programmes of NWO-MCG, the 
genomics Centres of Excellence and CSG that have been developed so far, in order to continue and 
consolidate, but most of all to further advance the agenda of ELSA genomics. Three aspects will be of 
particular importance:  
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1.Interactive methods: The effort to combine research and societal interaction will be continued. The 
international mid-term review committee strongly recommended CSG to further develop and improve its 
efforts to link research and interaction activities.4 The committee concluded that CSG has the “potential to 
become an international Centre of Excellence for “how to do” embedded ELSA research” (p.12). To fulfil 
this potential, the committee recommended CSG to a) further develop its method of embedded ELSA 
research and b) to strengthen in-house capacity for doing so (p.13). By developing this methodological 
profile, CSG uses the opportunity to increase its focus, to strengthen its “branding” as interactive ELSA 
centre and to intensify the relationship between research and communication activities.  
 
2.The governance of genomics applications: Genomics will affect all levels of society. This makes the 
question how to govern genomics science and technology an urgent matter for reflection. Special attention 
is needed for institutional and macro- issues, international relations and comparisons, and the issue of 
globalisation.5 
 
3. Societal tasks and trends: Genomics applications – ideally - provide an answer to important societal 
issues. Societal organisations and public interest groups often stress that an inventory of pressing societal 
concerns should precede agenda setting in research. The Ministries of Agriculture, Nature and Food 
Quality (LNV) and Health, Welfare and Sport (VWS) likewise emphasise that the genomics agenda 
should be shaped to address urgent societal themes and tasks.6 What are the most important issues for the 
future? A number of trends can be identified already: According to an analysis drafted by COGEM7 
together with CBD and the Health Council of the Netherlands, important trends in the domain of 
biotechnology are: (a) sustainable bio-energy, (b) blurring of boundaries between genetic modification and 
novel techniques for crop improvement, (c) increase of options for screening and diagnostics and (d) sub-
optimal utilisation of prospects for biotechnological developments in the Netherlands. Some additional 
issues could be added to this list such as the role of Bio-banking.8 The Ministry of Health, Welfare and 
Sport also mentioned the provision of information and education about health-applications, screening, and 
public-private partnerships. Furthermore, both LNV and VWS emphasise that the process of setting the 
biotechnology or genomics agenda requires a continuous dialogue between government, citizens and 
scientists. 
                                                 
4 External Research Review Centre for Society and Genomics (CSG) 2006. Quality Assurance Netherlands Universities (QUANU). January 2007.  
5 Maatschappelijke Aspecten van Genomics Onderzoek: continu leren en aanpassen. Programme Commissie MCG. Concept 20 maart.  
6 Kennis voor de samenleving. Voortgangsrapportage 2006. Implementatie Kabinetstandpunt brugfunctie TNO/GTI’s. Ministry of Health, 
Welfare and Sports (VWS) Social Tasks for Public health and Health Care. Den Hague, 2006. 
7 Netherlands Commission on Genetic Modification; Cf. Stakeholder workshop Trend Analysis Biotechnology 2007 (Utrecht 
March 30 2007). 
8 RGO, Advies Onderzoeksagenda Medische Biotechnologie, Den Haag, April 2006.  
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Working together  
The international mid-term review committee recommended that CSG should collaborate more closely 
with the other Centres of Excellence and intensify its contacts with policy and political audiences in The 
Hague. It is therefore not without reasons that the programme 2008-2012 is a co-effort of all Genomics 
Centres and focuses strongly on the issues concerning policy and governance. Besides, CSG has 
developed good contacts with a series of policy-networks which we want to further develop, use, inform 
and interact with in the future. Examples of these networks are the Forum for Biotechnology and Genetics 
(FBG), the Netherlands Commission on Genetic Modification (COGEM), the policy arenas of the 
Ministry of Agriculture, Nature and Food Quality and a number of initiatives at the Ministry of Health, 
Welfare and Sport.9 
CSG also profits from collaborations with a significant number of international partners. CSG is 
coordinator of a large ERA-NET – ERASAGE 10 - that brings together genomics funding agencies from 
nine different countries including Canada, Switzerland, Germany, UK, Norway, Finland, Israel and 
Austria. Also, CSG collaborates with a number of well-established sister organizations such as the Centre 
for the Economic and Social Aspects of Genomics (CESAGen, UK); the ESRC Genomics Policy Forum 
(UK), the Centre for Ethics at the University of Tartu in Estonia, the INSERM Institute in Toulouse (FR) 
and the Flemish Institute for Biotechnology (VIB) in Belgium. The activities of the VIB are of particular 
relevance because of their broad range of activities using the Dutch language. 
                                                 
9 Notably a follow-up of the “Agenda medical biotechnology” and “Biotechnologie als Open Beleidsproces”. 
10 European Research Area on Societal Aspects of Genomics. http://www.erasage.org/ 
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6. Scientific programme 2008-2012 
In the coming years, genomics science and technology will trickle down into the fabric of our society, 
while society will increasingly develop ways to determine the future development of genomics. This raises 
the question how to govern genomics in order to benefit from its potentials without doing harm to the 
environment, animals or individuals.  
The interactive development of genomics science and technology can be seen as an experiment 
from which we should learn. ELSA genomics does not provide a recipe for embedding genomics in 
society. Rather, ELSA genomics can be seen as a “test-bed” for studying the relationship between science 
and society. Rather than exposing society to new technologies in a trial-and-error manner, a test-lab is 
created by doing ELSA “trials” about possible effects and their assessment (Rip 2002, Krohn and Weyer 
1994). By combining research with societal interaction, society becomes a laboratory that generates 
knowledge about the interaction between genomics and society (De Vries & Horstman 2006). 
The agenda 2008 – 2012 includes three particular “test-beds”: The first and most important 
programme concerns the application and use of genomics. But it cannot be successfully fleshed out if we 
fail to address issues of agenda setting and of communication. Therefore, the second programme concerns 
the genomics agenda (how do scientific and societal transformations shape this agenda?), while the third 
programme concerns information, education and communication about genomics: 
I. Genomics Applications  
II. Genomics Agenda  
III. Genomics Education and communication  
 
Programme I Genomics applications 
Genomics science and technology will lead to the development of new applications and products such as 
diagnostic tests and nutraceuticals, novel consumer products and food, alternative energy resources or new 
generations of fertilisers. These developments first of all pose the question to what extent innovative 
genomics applications and goods are deemed necessary or desirable. What are the benefits of increased 
testing opportunities? What do different parties – e.g. citizens, professionals, policy-makers – perceive as 
desirable?  
Secondly, what are the conditions and prospects for both current and future genomics applications 
to become embedded in society? How should we govern innovative applications, particularly if such 
applications do not match with existing rules, regulations and (evaluation) practices? This requires more 
than simply “adapting” regulation and legislation. Rather, genomics challenges familiar notions and 
concepts such as risk, health, environment and “natural” and calls for new constellations to assess these 
implications. The development of nutraceuticals, for example, situated at the intersection between 
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medicine and life-style (choice), nicely illustrates this point. While medicines are evaluated on the basis of 
their effect (does it work?), food-products are evaluated in terms of risks (will it cause harm?). A useful 
assessment of novel products requires not just a change of practices but a new ways of thinking about 
health, food and what is being valued in both.  
Thirdly, innovative technologies pose the question what effects such applications have on the 
environment, on markets and on individual men and women. Will it still be useful or sensible to talk about 
“individual choices” of consumers, patients and citizens? To what extent will the DNA chip, the use of 
bio-markers in screening, bio-fuels and eco-genomics change our behaviours? The programme is divided 
in two themes: The first theme, Changing practices and policies, focuses on practices and institutions. 
What practices emerge as a result of the co-production of genomics and society? What is or should be the 
role of professionals, policy-makers, producers and legislators in this process? The second theme, Identity 
and behaviour, focuses on individuals and individual behaviour. How do individual patients, consumers 
and citizens deal with (the promises of) genomics applications?  
  
Programme II. Genomics agenda  
Society, we have argued, will increasingly be confronted with new genomics applications. These 
applications concern medical tests, industrial products, food products and the environment for example. 
What applications will see the light and will be successfully used not only depends on “internal” scientific 
developments. The agenda of genomics research is shaped by a complex set of factors such as funding 
possibilities (e.g. 300 million for genomics research), the organisation of knowledge production (e.g. the 
emergence of new fields such as bio-informatics and metabolomics), institutional frameworks (e.g. a ban 
on human stem cells), public opinion (e.g. the GM-debate) and the role of promises and expectations in 
the public domain (e.g. recent commotion about the “diet-pill”). This programme focuses on the genomics 
agenda: what shapes this agenda and what makes this agenda “societally” robust?  
Two themes will be further explored. The first theme, Transformation of knowledge production, 
studies the transformation of scientific practices and the role of genomics as a converging and enabling 
technology. Genomics has been described as the “informatisation” of life. Large amounts of bio-
information become available in electronic formats for researcher communities worldwide. What 
consequences does this paradigm change within the life-sciences have for the expected applications? The 
second theme, Knowledge & benefits, focuses on ownership, benefits and private/public constellations. 
How is bio-information produced and exchanged? Moreover, governments, funding agencies and research 
institutes are developing ways for reimbursing their investments in genomics as a “big science” 
phenomenon. How will societies benefit from their research investments?  
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Programme III Genomics Education and Communication  
Citizens, patients, consumers and professionals play a pivotal role both in discussions on genomics 
science and technology and in the acceptance and use of new genomics applications. A critical reflection 
on the meaning and uses of genomics applications requires knowledge and information about genomics. 
Preparing ourselves - and our societies – for the issues that genomics will raise, both now and in the 
future, requires information, communication and education. It will enable citizens, researchers, 
professionals and policy-makers to critically assess the implications and uses of genomics.  
Our ambition to combine research with societal interaction will be most prominent in this 
programme. It is divided into two themes. The first theme focuses on New forms of interaction. This 
includes organising as well as reflecting on new forms of public information, discussion, debate and 
dialogue. The second theme focuses on Education and Expertise. It includes organisation of and reflection 
on a series of education activities for young people, scientists, citizens and professionals. Thus, both 
themes focus on the one hand on the development of public interaction and education activities, and on the 
other hand on the evaluation and improvement of these interactions, based on assessments of effect, 
efficiency, impact and costs. 
 
Table 1: Programmes, Themes & Topics  
Programme Theme   Topics  
Changing practices and 
policies 
•  Institutional implications  
• Genomics governance  
• Bridging the gap between science & policy  
I.  
Genomics 
applications 
Identity and Behaviour • Identity and responsibility  
• Risk and behaviour  
• Consumer choices & consumer behaviour  
Transformation of 
knowledge production 
• The new production of knowledge 
• Promises, expectations & future scenario’s 
II.  
Genomics 
Agenda  Knowledge & Benefits  • Benefits & ownership 
• Setting the agenda  
New forms of public 
interaction 
• Public debate 
• Modes of Interaction 
• Information and behaviour 
III. 
Genomics 
Education and 
Communication Education and Expertise  • Empowering patients, consumers and citizens 
• Educating young people and (young) scientists 
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These programmes organise our domain, but they must not be seen as “compartments” separated from one 
another by fixed boundaries. Rather, they remain closely connected, and in various ways activities in one 
programme can and will be made relevant for activities in the other two. Some projects explicitly build on 
the results of previous efforts, as the ambition to understand and improve the conditions for embedding 
genomics often calls for sustained efforts to ameliorate practices, update policies and inform important 
stakeholders.  
The following paragraphs describe the three programmes in more detail. As each programme 
combines research and interaction, the programme describes both societal activities that are accompanied 
by research and research projects that include some form of societal interaction. After a short introduction 
of each of the six themes the text provides concise descriptions of research projects and activities. 
Research projects will be described in terms of question, background and deliverables, societal 
interactions in terms of activities, background and deliverables. Also the project manager, the 
organisational setting, the amount of fte’s available and the duration of the project are indicated. 
Since genomics is a dynamic field in terms of pace and scope it is hard if not impossible to predict 
what will be important issues and themes in the public and policy arena in the next few months or years. 
These might be converging technologies, IP policies or genetic screening for example. Thus, although it is 
important to develop a focussed and coherent agenda, it is also crucial to remain responsive to new and 
unexpected developments and emerging issues (in research, policy or society). We therefore have reserved 
12 % of the overall budget for future plans and developments. The programme committee (chapter 8) will 
develop the focus and content of these activities. 
 
Programme I. Theme 1: Changing practices and policies. 
The development of genomics applications and use calls for “genomics governance”. Governance 
basically refers to the ways in which genomics research is “governed”, that is: made possible, developed, 
monitored, applied and modified in the context of contemporary knowledge societies. “Good governance” 
starts from the idea that governance is participatory, consensus oriented, accountable, transparent, 
responsive, effective and efficient, equitable, inclusive and law-abiding.  
Whereas “genomics sceptics” are concerned that the available tools for monitoring and control 
will prove inadequate to address the novel risks genomics research entails, ranging from genetic 
discrimination to the creation of new organisms, genomics “believers” warn against regulatory inertia and 
cultural technophobia. While sceptics are concerned that genomics will reinforce a deterministic 
understanding of life and of ourselves (Lippman 1992, Nelkin & Lindee 1995), optimists argue that 
genomics information will empower individuals to manage their own health condition, and will provide 
patients and consumers with medicines and food products tailored to their genomic profiles. In the light of 
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these diverging expectations, genomics has become an important topic for governance (Gottweis 1998, 
2005). How can genomics be developed in such a way that its outcomes are tailored to genuine societal 
interests while societal risks are adequately addressed?  
The programme will compare a number of current and future applications. One of these 
applications is the development of new genetic tests and possibilities for screening. The recent extension 
of the Dutch newborn screening programme (heel-prick), from 3 to 17 diseases, can serve as exemplary 
case for future applications. It has been anything but a smooth process.11 What can be learned from the 
experiences of policy-makers, professionals and parents in this respect?  
With respect to future applications we will investigate how genomics and society co-evolve: how 
do new technologies shape new practices and vice versa? Genomics applications raise new (ethical) 
questions and ask for different institutions to evaluate and regulate the use of such applications. This not 
only calls for reflection, it also requires action in political and policy settings. Bridging the gap between 
policy, science and the public is an important issue of concern.  
 
Implications and applications: the embedding of genomics 
Question: what can be learned from the recent extension of the newborn 
screening programme from 3 to 17 diseases? Background: the current 
extension of the newborn screening programme serves as an example for the 
future when genomics technologies will enable the identification of many 
more treatable conditions for which screening is available, either as neonatal 
tests or tests that take place later in life (adulthood). What are the experiences 
of parents, policy-makers and professionals? How to organise future testing 
possibilities? Deliverable: Inventory of public and professional concerns, 
knowledge and attitudes; Identification of good practices for introducing new 
forms of genetic screening. 
I.1a  
Evaluation of the 
Heel-prick  
CMSB – Dr. Symone Detmar – in collaboration with NMC, National Institute for 
Health & Environment – 1.0 fte; 24 months 
Questions: what can be learned from the recent introduction of 
haemoglobinopathy (HbP) testing in the Netherlands? Background: As HbP 
mainly occurs in specific ethnic communities, the vision of stakeholders in 
migrant communities on the use of genetic screening for HbP for 
reproductive choices needs to be explored (religious leaders, youth workers, 
health care workers). What is the role and responsibility of GPs, midwives, 
youth care or prevention initiatives? Deliverables: Inventory of opinion of 
stakeholders of migrant communities; Agenda for governance of future 
testing and screening options. 
 I.1b  
Screening for 
Haemoglobinopathy 
CMSB –– Dr AMC Plass - in collaboration with NMC, patient organisation (Oscar) 
and Erfocentrum – 1.0 fte; 48 months 
                                                 
11 De Volkskrant 24 maart 2007; Medisch Contact, 2 & 9 March 2007. 
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Question: What is the appropriate legal framework needed for large scale 
applications of genomics in the domain of disease/prevention screening? 
Background: the prospect of an increasing number of new screening 
programmes calls for an assessment of current legislation, such as the law on 
population screening (WBO) or the law that defines the relationship between 
patients and carers (WGBO). Deliverable: roadmap for developing an 
appropriate legal framework for new genomics applications (health domain).  
I.1c  
Legal framework for 
the implementation 
of new genetic 
screening/testing 
possibilities CMSB – Prof. A. Hendriks- 1.0 fte; 48 months 
Question: What can be learned from past experiences concerning the 
implementation of new genomics knowledge? Background 1: Laboratory 
scientists, clinicians and ELSA researchers all have valuable experiences 
concerning genomics communication but do not necessary share these very 
often. This project will bring these different groups together. Deliverable 1: 
setting the agenda for future interaction and communication of science and 
society. Background 2: Many industrial products and patents will never be 
introduced on the market. Deliverable 2: Inventory of the lessons and hurdles 
of innovation processes; Identification of good practices of innovation. 
Background 3: The gap between high tech production methods and consumer 
preferences for more natural products potentially leads to negative attitudes 
towards these high tech production methods. How can this be understood and 
addressed? Deliverable 3: Roadmap for the introduction and management of 
plant genomics products.  
I.1d  
Learning from the 
past. Implementation 
and use of genomics 
knowledge 
CMSB – Prof. Dr. Jos van den Broek – 1 fte;18 months 
Kluyver Centre – Dr. Patricia Osseweijer - 1 fte; 48 months 
CBSG - Prof. Dr Bart Gremmen- 1 fte; 48 months 
Question: what are the ethical, legal and social issues relevant in multiple 
genetic testing for complex diseases? Background: Multifactorial diseases 
such as type 2 diabetes, osteoporosis, and cardiovascular disease are caused 
by a complex interplay of genetic and non-genetic factors, each of which 
entails a minor increase in the risk of disease. However, to assess these tests, 
we use values and measures that are related to monogenetic disorders. But, 
the predictive value of multiple genetic tests and the inheritance of genomic 
profiles is lower than in the case of monogenic diseases. Deliverables: 
Inventory of ethical, legal and social issues concerning multiple genetic 
testing; Tool for evaluating these tests. 
I.1e  
Future testing of 
multifactorial 
diseases  
CMSB – Dr Cecile Janssens – 1 fte; 12 months (1 additional fte funded by CMSB) 
 
Government arrangements concerning new (technology) practices 
Question: How do medical, forensic and commercial bio-banks shape and 
transform research practices, criminal law practice and the consumer health 
market? Background: the storage of tissue, blood and information in medical, 
forensic and commercial databases challenges the ways in which we evaluate 
the use and necessity of medical research, forensic practices and the promises 
of stem-cell research for example. Of particular importance are notions 
concerning privacy, information, ownership, blame and bodily integrity. 
Deliverable: Agenda for the future government of DNA databanks.  
 I.1f  
DNA databanks  
Rijksuniversiteit Groningen – Dr Hans Harbers – 1 fte; 24 months. 
Universiteit van Amsterdam – Dr Amade M’Charek - in collaboration with Forensics 
Genetics Consortium Netherlands and Rathenau Institute – 1 fte; 24 months. 
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Question: how should preventive genomics technologies be governed? 
Background: genomics applications will lead to a further expansion of 
preventive technologies concerning food, health, safety and the environment. 
Governments tend to emphasis the benefit of prevention but prevention may 
include a number of tensions such as between public and private 
responsibilities; between risk and precaution; between have’s and have-nots 
and between today’s information and future hopes. Deliverables: Critical 
analyses of preventive genomic technologies; Agenda for future governance.  
I.1g  
Governance of 
Prevention 
University & Project manager: to be assigned - 1 fte; 48 months 
Question: to what extent do patients and patient organisations influence the 
governance of new genomics technologies? Background: It is often claimed 
that patients and patient organisations are increasingly involved in agenda 
setting processes concerning the development and use of new genomics 
applications. The contribution of patients, it is often said, is unique as patients 
experience what it means to be ill and to live with a certain disorder or 
disease. Deliverable: agenda for future patient participation.  
I.1h  
Patient participation 
in genomics: shaping 
policy and research.  
CSG – Dr. Annemiek Nelis – In collaboration with VSOP - 1 fte; 48 months  
 
Reducing the gap between science and policy. 
Question: How to align research, policy development and public debate for 
developing genomics-based alternatives to animal testing? Background: 
Toxicogenomics research may significantly reduce the number of animals 
used in scientific research. It opens up possibilities for developing reliable in 
vitro and in silico (bioinformatics-based) models as alternatives to using 
animals in vivo. Implementation and acceptance of these tools may be 
hampered by current legislation and policy bodies. This project studies the 
gap between science, policy and public discourse, building on policy- 
initiatives already undertaken by the toxicogenomics consortium. Deliverable: 
tools for ethical assessment of alternatives to animal testing; Guidelines for 
assessment on programme level (as opposed to project level).  
I.1i 
Toxicogenomics: 
acceptance and 
implementation of 
genomics based 
alternatives.  
CSG- Prof. Dr. Hub Zwart/Dr. Annemiek Nelis – in collaboration with NTC and the 
Dierenbescherming. 1 fte; 48 months  
Question: How to bridge the gap between viral genomics, health policy and 
public discourse? Background: Developments such as the increase of global 
mobility and climate change create risks for new infectious diseases and entail 
new challenges for viral genomics, notably in terms of respiratory infections. 
Are we heading for an influenza pandemic? Are these concerns phobic or 
realistic? And should the latter be the case: are we (the public, policy makers, 
GPs, researchers, etc.) ready for such an event? The project makes use of 
policy- initiatives that are already undertaken by the viral genomics research 
community. Deliverable: roadmap towards a viral genomics policy.  
I.1j 
Viral genomics: 
Preventive strategies 
for 
novel respiratory 
virus infections 
CSG – Prof. Dr Hub Zwart/Dr Annemiek Nelis – in collaboration with VIRGO 
Consortium – 1 fte; 48 months  
Activity: organisation of projects to explore contentious issues with publics 
and professionals with the aim to inform Dutch Parliament. Potential issues: 
genetic screening (up-date of the citizens jury of 1993); forensic science 
(linking with EU project INES), influenza or alternatives for animal testing.  
I.1k 
Informing 
parliamentary debate  
To be developed with Rathenau Institute – 0.1 fte; 24 months 
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Activity: A series of dialogues with experts and non-experts from science, 
policy, politics, journalism and arts. This series aims to feed discussion and 
debate concerning the societal agenda of genomics. The debates will focus in 
particular on the relation between science and policy.  
I.1l 
A Conversation on 
Genomics 
CSG – in collaboration with Nederlands Gesprek Centrum (NGC) & Internationale 
School voor Wijsbegeerte (ISVW) – 0.1 fte; 24 months  
 
Programme I. Theme 2: Identity and Behaviour 
In the future, more and more information about individual genomes will become available. It is expected 
that in a not so distant future, genomics technologies will be used to sequence the genome of individuals. 
Consequently, individuals may receive information about their future health status, the health of their 
progeny, the most suitable diet and the most effective medication. Individuals may be falsely assured 
about their health status or they may be “empowered” to manage their own health and postpone health 
problems occurring later in life. How desirable are genetic testing and genetic screening? What are the 
perceived advantages, risks and hurdles?  
Genomics information and applications bear an effect on and concerns not only human health but 
also individual behaviour. Knowledge about the DNA of individuals, plants or micro-organisms may 
affect or change the images we have of ourselves as patients, consumers or citizens. Building on the 
results of a number of earlier projects, this theme elaborates how genomics shapes identity. And how does 
the ‘genomics identity’ affect professional, public and individual responsibilities?  
Genomics not only applies to genetic testing and genetic screening. Whether functional foods, 
bio-fuels, over-the-counter genetic tests or genomics-based food products will be used, depends to a large 
extent on the behaviour of (individual) consumers. European consumers have shown reluctance to accept 
GM-food. It is questionable whether and under what circumstances they are willing and interested to buy 
tasty tomato’s that are created with the help of genomics. Similar questions can be raised with regard to 
bio-fuels and enhanced food products that claim to respectively improve the level of sustainability and 
health. A further understanding of the behaviour, knowledge and values of consumers is necessary to 
understand and foresee the public responses to genomics, to align the genomics agenda with consumer 
preferences and to increase the likelihood of particular genomics applications to survive on the market.  
 
Genomics applications: a desirable test? 
Activity: A series of virtual and real-life polls and dialogues with patients, 
pregnant women, parents of newborns and representatives of the general 
pubic. Question: are new genetic tests seen as desirable, comprehensible and 
applicable? Deliverable: Inventory of views and arguments concerning 
genetic testing; Evaluation of interaction and communication with women, 
parents and members of the public.  
I.2a 
The societal demand 
for new genetic tests.  
CSG – Dr. Annemiek Nelis - in collaboration with Erfocentrum and NMC – 0.1 fte; 
48 months  
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Activity: A series of virtual and real-life polls and dialogues concerning 
Celiac disease. Question: If it is possible to screen every citizen for Celiac 
disease, should we do this? Background: People who suffer from Celiac 
disease do not tolerate gluten. Gluten are present in numerous varieties of 
grain and therefore a major ingredient in many food products. Celiac disease 
is known to be under-diagnosed. This means a large part of those affected do 
not know that they have Celiac disease. Deliverables: Inventory of views and 
arguments concerning Celiac screening; Evaluation of interaction and 
communication with patients, professionals and lay-people.  
I.2b 
The societal demand 
for genetic screening 
CSG- Dr. Annemiek Nelis- in collaboration with Celiac Disease Consortium & NCV 
Dutch Celiac Society – 0,1 fte; 48 months 
Question: If it would be possible to predict our individual life-span on the 
basis of genomics, would people want to know? Background: Ageing is an 
important issue for the future. We all want to live longer in good health. 
Would longevity change people’s lives and the choices they make in life? 
Activity: The project will make use of a web -based discussion organised 
through the web-forum of popular life-style magazines (e.g. Libelle, Viva). 
Deliverable: Inventory of factors that determine usefulness or desirability of 
life-span estimates. 
I.2c 
Ageing  
Ageing consortium - Prof. Dr Inez de Beaufort- 1.0 fte; 24 months  
 
Identity, risk and responsibility 
Question: What ethical questions are involved in the possibility to screen 
youngsters at an early age (before deviant behaviour is manifest)? 
Background: Behavioural genomics promises to add to developing 
personalised and effective services. Early detection, prevention and the 
manipulation of stimuli in the environment of individuals are examples of a 
more personalised and effective approach. This project will consider a number 
of cases concerning problematic behaviour in young people (conduct 
disorders). What are, should or could be the roles and responsibilities of 
parents and professionals? Deliverable: Agenda for future application of 
behavioural genomics screening tests.  
I.2d 
Behavioural 
Genomics  
University of Maastricht - Prof. Dr Guido de Wert – in collaboration with AZM – 1 
fte; 24 months 
Question: To what extent will genomics provides tools to enhance human 
beings? Background: Building on the CSG course “Genomics and identity” 
this project explores the question of human enhancement using the work of 
two philosophers: Michel Foucault and Peter Sloterdijk. Can genomics 
become a tool for enhancement? What moral limits should be set? Or have 
human beings always been shaped by knowledge and technologies and should 
we use these technologies to further improve humankind? Deliverable: 
Inventory and assessment of arguments, positions and theories concerning 
genomics and human enhancement. 
I.2e 
Genomic Identities 
& human 
enhancement.  
University of Amsterdam - Prof. Dr. Gerard de Vries – in collaboration with Institute 
for Interdisciplinary Studies – 1 fte; 48 months 
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Question: how do new genomics technologies enable “reproductive choice” as 
the officially professed aim of prenatal screening? Background: Until recently 
‘choice’ in prenatal screening meant: being given the opportunity to accept or 
decline a standard offer of testing (and to decide about having or not having 
an abortion in case of a serious defect). Genomics and molecular technologies 
make it less obvious what the standard offer should include, or whether there 
should be a standard offer at all. Should ‘enabling reproductive choice’ be 
given the wider interpretation of allowing pregnant women/couples to 
individually decide what information about the foetus to receive or not to 
receive (i.e. the concept of ‘individualized choice’)? Deliverable: road map 
for future use of new reproductive technologies.  
I.2f 
Individualized choice 
in prenatal 
screening? 
University of Maastricht – Prof. Dr Guido de Wert/Dr W. Dondorp- 1 fte 24 months.  
Question: how do predictive tests for longevity and concomitant lifestyle 
advice change societal practices? Background: Genetic tests may indicate 
susceptibilities for disease in old age, or may deliver longevity estimates. 
Predictions about individual health, illness and life span may influence the 
course of life or life decisions. However, it may also change pension schemes, 
insurance, and health care goals. Do pension plans, or (health) insurance 
companies have a right to know, is there a duty to inform, particularly when 
susceptibility is linked to lifestyle? Deliverable: Inventory of issues related to 
future uses of genetic predictive testing concerning longevity.  
I.2g 
Estimating Risk: 
Ageing & Longevity 
Ageing consortium - Prof. Dr Inez de Beaufort- 1 fte; 24 months  
Question: How do individuals conceptualise genetic factors compared to other 
influences upon health and illness? Background: both family history and 
DNA information can be used to promote lifestyle changes that are known to 
be effective in reducing the risk of developing type 2 diabetes or 
cardiovascular disease. It is assumed that these different types of information 
will be valued differently by for example obese parents than by none-obese 
parents. These parents may see the obesity of their children as genetic or 
behavioural, as avoidable or fate. Also, different communities may use 
different explanations. Particular attention therefore will be given to the role 
of ethnicity and culture. Deliverable: Roadmap towards the application and 
use of tailored intervention strategies concerning metabolic syndrome.  
I.2h 
Tailored intervention 
strategies  
CMSB – Prof. Frank Snoek – 2.0 fte; 24 and 48 months 
 
Consumer behaviour 
Question: what are consumer preferences concerning high-tech food such as 
genomic tomatoes and potatoes? Background: Consumer behaviour often is 
tested in particular contexts such as through surveys or questionnaires. This 
study focuses on the actual behaviour of consumers at home (preparing meals, 
cooking etc.) and while eating out. What role do concepts such as “organic 
food”, safety and sustainability for example have in the actual behaviour of 
consumers concerning genomics products? Deliverable: Contribute to agenda 
setting for plant genomics research.  
I.2i 
Consumer and 
Consumer Behavior 
 
CBSG – Prof. Dr Bart Gremmen – in collaboration with “The Restaurant of the 
Future” - 2 fte; 48 months 
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Programme II. Theme 1: Transformation of knowledge production  
The genomics agenda first of all is shaped by transformations of knowledge production. The Human 
Genome Project (HGP) symbolises the emergence of genomics as a new techno-scientific field (IHGSC 
2001, 2004). In contrast to “traditional” genetics and biotechnology, and depending on evolving 
technologies for high throughput biochemistry and bioinformatics, genomics opts for a whole genome-
oriented, rather than for a single gene-oriented approach. It has resulted in a steady stream of ever-larger 
and more complex genomic data sets, thus transforming the study of virtually all forms of life. In other 
words, genomics is not a particular branch of biology, nor simply a set of research tools for high through-
put analysis. Rather, it is transforming the ways in which research in the life sciences is done (Collins et al 
2003).  
In various research fields, such as ecology, biomedicine and toxicology, genomics has provided 
researchers with new research tools and strategies that allow them to reframe and redefine some of the 
basic questions concerning living nature. Being a “converging field”, genomics brings together large 
numbers of researchers from various backgrounds. As a result, research is done on a much larger scale 
than in the past and in a more interdisciplinary manner. Initially, the focus was on sequencing the genomes 
of model organisms (worm, fly, plant, mouse and man) but by now much of the research has entered the 
post-sequencing phase, and this involves a shift from structural genomics (sequencing genomes), to 
functional genomics (understanding genomes) and related areas such as proteomics and metabolomics.  
Expectations about genomics applications emerge in different forms and formats. Scientists, 
media, ELSA-researchers, policy makers, story-writers and representatives from industry all make 
promising claims about genomics, paint interesting future scenarios and organise plots and pilots that, 
eventually, may become irreversible. The development of personalised medicine, personalised diets, 
sustainable and renewable energy, tasty tomatoes and “tailored” forms of fertilisers emerge in stories, 
policy views and innovative networks. How do promises, expectations and scenarios help to shape future 
applications? The former not only describe possible futures, they actively contribute to the shaping of 
these future by mobilising resources, time and energy of research groups and stakeholders such as funding 
agencies and patient or consumer organisations (Brown & Micheal 2003).12 ELSA genomics research 
itself plays an active role. It questions, but also amplifies these promises. 
 
 
 
 
                                                 
12 The NGI initiative is a good example, producing great expectations and mobilising, on the basis of these promises, resources 
and researchers to fulfil them. 
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Transformation of knowledge practices: implications for future use 
Question: what is the role of genomics in the “informatisation” of life and of 
bioinformation in the genomics paradigm? What new roles and 
responsibilities does this imply for researchers (as producers and users of 
bioinformation data)? Background: Genomics as a converging and enabling 
field symbolises increase in scale, global interdisciplinarity and exchange in 
the context of international networks. Notably, it is a convergence of 
molecular and computational approaches. Biobanks are emerging as 
genomics’ principal research tool. Deliverables: Inventory of strategies for 
agenda setting; Guidelines for bio-information exchange; (3) Roadmap for 
empowering bioethics to address macro-issues of bio-information 
management 
II.1a 
Genomics profile: the 
bioinformation society 
CSG - Prof. Dr. Hub Zwart – In collaboration with NBIC – 2.2 fte; 24 – 48 months  
Questions: How to assess the societal profile and prospects of ecogenomics? 
Background: Ecogenomics as a converging field is said to represent a new 
paradigm and revolution in the life sciences, a synthesis of molecular 
(“reductionist”) and ecological (“holistic”) approaches. This “new 
synthesis” implies a new vision of nature, new possibilities for technological 
interactions with nature, more responsive to nature’s potentials, opening up 
possibilities for fine-grained, nature-friendly and sustainable applications. 
Deliverables: Roadmap for a socially robust ecogenomics agenda; Tools for 
framing anticipatory debates; Inventory of societal implications and 
promises in various practices 
II.1b 
Societal profile of 
ecogenomics as a “new 
synthesis” 
CSG - Prof. Dr. Hub Zwart – In collaboration with the Ecogenomics Consortium, 
the Ecogenomics Platform and Prof. Dr. John Dupré (Egenis)– 1.2 fte; 48 months 
 
Genomics knowledge: promises, expectations and future scenario’s 
Question: How do health claims concerning nutrigenomics emerge in 
settings outside the laboratory and how do they effect the (future) 
development of genomics? Background: Nutrigenomics, perhaps more than 
any other genomics application, is surrounded by promises and claims 
(‘Health is the future of nutrition’). Such claims generally act as sale booster 
to promote new products. However, health claims are not made in 
laboratories. They emerge in boundary zones between (inter)national 
regulations, pilot studies, experimental knowledge, commercial strategies, 
editorials in scientific journals and reports by the media. Deliverables: 
Guidelines for assessing health claims. 
II.1c 
Nutrigenomics practice 
beyond the laboratory.  
CSG – Dr. Annemiek Nelis / Prof. Dr. Hub Zwart – In collaboration with 
Nutrigenomics consortium – 1 fte; 24 months  
Question: How do new genomics applications (such as bio-markers and 
diagnostic tests) affect institutional innovation? Background: Genomics 
involves significant changes not only of research networks but also of the 
various ways in which genomic knowledge and technologies are embedded 
in health care practices. Hospital-based networks of researchers, clinicians 
and funding bodies have always been pivotal in the creation of genetic 
knowledge and its introduction in clinical practice. Deliverable: Roadmap 
for institutional embedding of genomics. 
II.1d 
The changing 
innovation system in 
the area of genomics  
University of Twente - Dr. D. Stemerding – 1.0 fte; 24 months 
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Question: In what ways may literary sources contribute to our ability to 
anticipate and critically assess the genomics future? Background: Research-
based novels may be read as literary experiments or future scenarios, as 
efforts to flesh out what the development of particular technologies may 
bring to society. Novels may function as resources for analysing the future 
potentials (and potential futures) of genomics, as extrapolations of 
laboratory developments to real-life settings. Deliverable: developing tools 
for using genres of imagination in public debate and policy development 
II.1e 
Anticipatory novels as 
test-beds for genomics 
futures 
CSG – Prof. Dr. Hub Zwart - 1.0 fte; 48 months 
University of Maastricht – 1.0 fte; 24 months 
Question: How can scenario studies facilitate the development of future uses 
of genomics knowledge for a number of common disorders such as diabetes, 
arthritis, Alzheimer disease, cancer, asthma and multiple sclerosis? 
Background: Building on the results of current interactive scenario studies, 
socio-technical scenario construction will be used as a tool to explore 
particular “innovation journeys” in the field of genomics. Deliverables: 
Tools for assessing and developing prevention oriented practices in public 
health genomics. 
II.1f 
Future scenario’s or 
“innovation journeys” 
in public health 
genomics 
 
University of Twente - Dr. D. Stemerding – 1.0 fte; 48 months 
 
Programme II. Theme 2: Knowledge and Benefits  
Genomics science and technology is a global enterprise. The local knowledge of indigenous people in the 
Andes region about wild tomato species, for example, plays a key role in the identification of genetic 
materials for commercial uses. To what extent do local stakeholders profit from commercial 
developments? How to guarantee that they will profit fairly from the benefits of genomics developments?  
It is as yet unclear to what extent genomics reduces or reinforces global differences in terms of 
power, affluence and participation. According to the WHO, genomics knowledge is most relevant to 
developing countries, but these countries do not always profit from the development of this knowledge 
(WHO 2002, Thorsteindottir et al 2003). At the same time, the life sciences are booming in countries such 
as India and the Far East. The effect of the genomics “industry” on geo-political relations clearly is an 
issue for concern and study. Who, in other words, profits from genomics knowledge?  
Knowledge production, by implication, produces and transforms power relations. Genomics is a 
technology with great innovative potential as it promises to produce a better world for all. However, 
different interests may be served at different moments in time. It is important therefore to ensure that the 
genomics agenda matches the needs of society and does so without causing harm, damage or unnecessary 
risks to individuals, biodiversity and the environment. To ensure that the genomics agenda is relevant for 
society and addresses the needs of (particular) societal groups, a critical assessment of this agenda is 
called for.  
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Globalisation, ownership and public-private interactions 
Question: How to reduce the global genomics divide between rich and 
poor in terms of access to knowledge? Background: Whereas patenting 
systems have contributed to the growth of science, it becomes increasingly 
clear to international actors such as FAO and NGO’s that the existing 
patenting system is seriously flawed with respect to global public goods, 
local knowledge and the use of resources. Deliverable: Tools for assessing 
new proposals for reducing the genomics divide. 
 II.2a 
Towards a fair and 
global-local just IPR 
(Patenting) system for 
genomics 
Wageningen University & Research Centre (WUR) - Prof. Dr Michiel Korthals – 
1.0 fte; 48 months  
Question: To what extent will public-private consortia further the 
innovation process? Background: Like other “big science” projects such as 
nanotechnology and climate change, genomics is organised in large 
public/private consortia that are partly funded with public money. Besides 
assessing these projects in terms of “return on investment”, it is important 
to know what the mix of public and private funding adds to the innovation 
process in comparison to alternative funding strategies (e.g. open 
innovation or full-scale public funding). Deliverable: Comparative 
inventory of best practices for funding innovative research. 
II.2b 
Public private 
partnerships: genomics 
governance  
 
University & Project manager: to be assigned – 1.0 fte; 24 months 
Question: How to improve participation of local knowledge producers 
(e.g. farmers) in decision making processes concerning their own 
agricultural products and livelihood? Background: The Preduza project 
aims to use existing wild tomato species to develop sustainable production 
technologies that can be adopted by small local farmers in developing 
countries. Deliverable: Roadmap for empowering farmers for agenda-
setting in developing countries. 
II.2c 
Giving the tomato back 
to the Andes: 
empowering local 
knowledge producers in 
developing countries CBSG – Prof. Dr. Bart Gremmen – 1 fte; 48 months  
 
Setting the genomics agenda 
Question: What are the potential opportunities and bottlenecks for 
sustainable production, regulation and global trading of industrial 
genomics products? Methodology: A number of landmark cases related to 
industrial genomics products, such as the issue of land-use for biomass 
production, will be discussed in three international expert meetings. 
Deliverable: Roadmap for improved public interaction and regulations, 
specifying the responsibilities of stakeholders involved.  
II.2d 
Identifying issues for the 
Genomics Agenda (1): 
industrial genomics 
Kluyver Centre – Dr. Patricia Osseweijer – 2.0 fte; 36 months 
Activity: Involving stakeholders in the development and use of genomics 
in a timely and anticipatory manner. Background: In 2005, CBSG started a 
Societal Interface Group (SIG) with members coming from various 
societal backgrounds and networks in order to allow public voices to 
become audible (at a stage when they can still influence research 
priorities) and also as a test-bed for communication strategies of the 
CBSG. The project will organize SIG meetings and analyze the process, 
comparing it with alternative attempts to involve society in innovation. 
Deliverable: Develop and assess good practices for timely stakeholder 
involvement in agenda setting.  
II.2e 
Identifying issues for the 
Genomics Agenda (2): 
Plant Genomics 
CSBG – Prof. Dr Bart Gremmen –Societal Interface Group  
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Activity: Setting the societal agenda for genomics. Background: In the 
past two years CSG has organised a panel of “societal experts” (artists, 
politicians, scientists, medical professionals, people from industry and 
journalists) to define “a Societal Agenda for Genomics”. Rather than 
taking genomics as a starting point, these discussions will start from the 
question “what are the societal tasks for the future?” CSG will continue 
this process of critically assessing the genomics agenda from a societal 
point of view, focusing on issues such as globalisation, eco-genomics and 
medical genomics. Deliverable: Agenda for genomics research tailored to 
addressing urgent societal issues 
II.2f 
Setting the societal 
agenda for genomics  
CSG – Drs Frans van Dam – in collaboration with public interest groups and 
ERASAGE partners – 0,3 fte; 60 months 
Question: How can upstream deliberations improve the fairness and 
societal potentials of research agendas? Background: Research priorities 
are framed by partners involved in agenda setting on micro, meso and 
macro levels. This involves problems of inclusion (e.g. representation of 
non-experts) and of differential framing. The extent to which stakeholders 
have a voice in setting research agendas often depends on value conflicts. 
Moreover long-term consultations on innovative processes require 
learning infrastructures for both scientists as others. First, this has 
implications for research ethics. Deliverable: Roadmap towards fairness in 
agenda setting; tools for addressing value conflicts in agenda setting. 
II.2g 
Upstream deliberations 
in genomics innovation 
 
 WUR - Prof. Dr Michiel Korthals – 1.0 fte; 24 months 
 
Programme III. Theme 1: New forms of public Interaction 
CSG aims to improve the public debate on genomics. The public, however, often is portrayed by 
scientists, media and industry as emotional (as opposed to rational), ill-informed and ill-equipped to judge 
the potential benefits and risk of genomics science and technology. The values, ambitions and hopes of the 
general public are often presented in terms of binary options: either pro or against genomics.  
The idea that critical responses to or even rejection of genomics would be avoided if the public 
was better educated, still seems to prevail among many scientists and representatives from industry. Many 
still believe that if the public would know more, the public would know better. However, social scientists 
have repeatedly shown that this approach, known as the ‘deficit model’, is far from valid. The public 
simply has different reasons, different values and different types of arguments to reject, distrust or simply 
ignore (genomics) science and technology developments. Besides, genomics is not something that people 
are for or against. Most people embrace for example new possibilities that genomics has to offer for 
medicine and disease-prevention while they are at the same time much more critical or sceptical about the 
development of genomics in the field of agriculture and food production.  
To improve the public debate, the life-sciences are in need of a new ‘social contract’ (Lubchenco 
1998) with society to align public concerns and public stakes with the potential benefits of genomics. This 
programme aims to inform and involve the public in an early stage of the development of genomics so that 
it can assess and anticipate future uses. This requires first of all a better understanding of the public 
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reactions and responses to the (perceived) promises and risks of genomics science and technology. 
Secondly, this requires a better understanding of the different forms of interaction that the public 
appreciates. While ten to fifteen years ago much discussion and debate took place in smoky cafés or 
similar venues, today the new media have opened a range of possibilities that allow for much larger and 
much more frequent interactions. These new types of interaction deserve to be tested, evaluated and 
explored. 
 
Past and current debates 
Question: What can be learned from past pubic debates on genetics, 
biotechnology and genomics? Background: Following early public debates 
on new innovative technologies (such as nuclear power), social scientists 
have written numerous studies concerning the public debate on genetics, 
biotechnology and genomics. Important concepts are public engagement, 
public understanding and interactive methods. Deliverable: Inventory of the 
literature on public discussion and debate concerning genomics; Tool for 
future development and evaluation of public discussion and debate.  
III.1a 
Learning from the 
past: debates on 
genetics/genomics.  
CSG – Dr Annemiek Nelis / Prof. Dr. Hub Zwart – In collaboration with Prof. Dr. 
Brian Wynne (CESAGen UK) – 0.25 fte; 48 months  
Question: How can popular culture, philosophy and Bio-art be used to 
improve life science communication? Background: Recovering public trust 
will continue to be the most important issue in the process of transferring 
science and technology to the market. This project will develop and evaluate 
new forms of public engagement. Deliverables: Guidelines for science 
communication and risk governance; Tools to facilitate upstream 
engagement in agenda-setting practices. 
III.1b 
Public voices in life 
sciences  
CBSG - Prof. Dr Bart Gremmen – 0.5 fte; 6 months  
 
New modes of interaction 
Activity: organisation of both virtual and real-life dialogues. Background: in 
2006/7, a pilot was conducted in co-operation with, among others, popular 
life-style magazines such as VIVA and Ouders van Nu. Discussion started 
with the publication of an article in these magazines on a particular 
genomics application (e.g. genetic screening). Readers were invited to 
participate in a discussion via the Web in which genomics experts 
participated as well. Live-debates took place at different locations. Question: 
what are the impact and effects of these debates? Deliverable: A series of 
public dialogue, Guidelines for organising interactive discussions.  
III.1c DNA Dialogues 
 
Ageing 
Animal testing  
DNA-Databases  
Food or Fuel?  
DNA Forensics  
Genetic Screening  
And more… 
CSG – Drs Frans van Dam & Genomics Centres – 0.2 fte; 60 months 
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Activity: Using new interactive technologies for public communication and 
interaction (e.g. SMS- polls; web-logs and chat-rooms; HYVES, virtual 
worlds such as Second Life).13 Background: CSG organises, studies and 
evaluates Web-discussions as well as the use of performing arts and bio-art 
and documentaries. In the period 2008 – 2012 a number of new interactive 
approaches will be explored, tested and evaluated. While some of these 
options can already be identifies as possible options, others will emerge in 
the years to come. Question: what are the impact and effects of novel 
interactive technologies on public communication, interaction and dialogue? 
Deliverables: Series of public discussions; Evaluation and identification of 
good practices for organising interactive discussions.  
III.1d 
New Modes of 
Interaction & 
Communication  
Vrije Universiteit - prof. Dr Frans Meijman – 1.0 fte ; 24 months.  
Kluyver Centre – Dr Patricia Osseweijer  
CSG – Drs Frans van Dam & Genomics Centres – 0.25 fte, 48 months.  
 
Provision of information to patients, citizens and consumers 
Activity: Organisation of information days for cancer patients and their 
families. Background: the Cancer consortium organised a first successful 
event on March 10th 2007. During this event, the cancer genomics Markt-
plaza attracted more than 1,300 individuals and obtained substantial media 
attention. Question: How can visualisation contribute to a better 
understanding of current genomics information by patients and 
professionals? Deliverables: Two large-scale information days; Assessment 
and development of tools for using visual representations of genomics 
knowledge in clinical decision making. 
III.1e 
Information day for 
consumers, citizens or 
patients. 
 CGC – Prof. Dr. Arend Jan Waarlo – 0, 7 fte; 48 months. 
Question: How to communicate genomics knowledge and information to 
consumers? Background: Public discourses on genomics often refers to 
“GM food” and GM crop. When being asked, many consumers refuse GM 
products. However, when shopping, few consumers bother to be 
knowledgeable about the ingredients shown on the labels of products. How 
desirable is it to provide more and more in-depth information to consumers? 
Deliverable: Analyses and evaluation of consumer needs; Guidelines for 
professionals to communicate about genomics science.  
III.1f 
Consumer information 
& Communication 
 CBSG – Prof. Dr. Bart Gremmen – 2 fte; 48 months  
Question: How do visualisations of genomics shape the understanding and 
normative values that individuals ascribe to genomics? Background: it has 
been suggested that visualisations of genomics enhances the understanding 
of genomics knowledge and information and enriches public debates while 
avoiding polarised positions. One project focuses on patients and 
professionals, a second project looks at the “visions of nature” that patients 
associate with genomics information. Deliverables: evaluation of 
visualisation practices; Guidelines for improving these practices.  
III.1g 
Visions of Genomics  
CGC – Prof. Dr. Arend Jan Waarlo – 0, 7 fte; 48 months. 
CSG – Prof. Dr Hub Zwart – 0, 2 fte; 60 months. 
 
 
                                                 
13 Several organizations, such as the broadcast corporation BNN and ABN-AMRO for example, have recently opened a branch in 
second life. See www.secondlife.com. 
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Transformation of behavior 
Question: What knowledge, emotions and visions motivate people to 
change their habits for example to reduce energy and change their attitudes 
in food choice? Background: The development of (pro-active) 
communication strategies requires an understanding of the effectiveness of 
communication activities. This project focuses on the development of novel 
forms of interaction (such as the Three-E-model Entertainment, Emotion, 
Education). Deliverable: development of tools and guidelines for 
communication and communication strategies.  
III.1h 
Social responsibility 
through upstream 
involvement in 
development and use of 
genomics applications 
Kluyver Centre – Dr. Patricia Osseweijer – 1 fte; 48 months. 
Activity: Organisation of a large-scale public survey among the Dutch 
general public. Background: NGI and CSG have twice (2002, 2005) 
conducted a public survey to evaluate both knowledge and attitudes of the 
public towards genomics. This 2-year survey will be continued as it 
provides an excellent opportunity to follow the development of knowledge 
and attitudes in the general population. Deliverables: Web-based survey on 
public attitudes. 
III.1i 
Public Survey  
 University of Twente – Dr Jan Gutteling. 
 
 
Programme III. Theme 2: Education and Expertise  
It is a broadly shared idea that the involvement of patients, consumers and citizens in decisions on science 
and technology will lead to more inclusive, more democratic and more robust policies, - hence good 
governance. However, public participation presupposes that the public has knowledge and information 
about the subject at hand. This is crucial for a critical understanding and assessment of genomics and its 
applications. Education and the fostering of expertise about genomics is therefore an important component 
of our programme. In the next five years, the genomics centres will organise and coordinate a broad 
programme, thereby linking different networks and initiatives. 
In the past few years, the Genomics Centres of CBSG, CMSB, CGC, Kluyver Centre and NBIC 
each have developed a “mobile DNA-lab” for upper-secondary education (DNA-labs on the Road). These 
labs have proven to be an excellent tool for education and the provision of information about genomics.14 
The labs embody an interesting mix of knowledge-transformation, hands-on-experience with genomics 
science and illustrations of genomics applications. Each lab consists of 4 hours in total (2 hours hands-on 
work with scientists) and includes tutor-instructions for teachers and students. The Genomics Centres 
regard the DNA-labs as the starting point for a variety of public activities that will bring genomics closer 
to the public.  
. In the period 2008-2012, the Centres will develop a (common) virtual labs and embed the mobile 
labs in the science centres in the Netherlands. One lab will be developed and organized together with the 
Forensic Genetics Consortium and Science Museum Naturalis. Also, the Genomics Centres have 
                                                 
14 CSG Newsletter, No 11 (January 2007), p. 2. 
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approached the organisation of the science week (Foundation NCWT) with the offer to co-organise the 
2008 Science Week around “In the genes” (Het zit in de genen).  
The labs are anything but a stand-alone activity of the Genomics Centres. They are firmly 
embedded and linked to the website www.watisgenomics.nl, a site with information for the general public 
and upper-level high school students. It contains both general lemmas and thematic issues. The site plays a 
pivotal role, both in informing the public about genomics and in the organisation of events, such as the 
mobile labs. In the near future, the site will provide more information, assignments and interactive tools 
for upper secondary school students. Also, the site will use more interactive tools (e.g. questionnaires) and 
listings of news and events. Last but not least, the site will provide more comprehensive basic theory and 
facts about genomics. Watisgenomics.nl is linked to and part of the “Virtueel kenniscentrum 
biotechnologie” of the Dutch Government, a portal that aims to improve access to information on 
genomics and biotechnology. 
The Genomics Centres collectively are also responsible for Imagine. This is a school competition 
involving scientists, school students and the media in order to achieve tangible results in 
developing countries with the help of life science and biotechnology. Upper secondary school children 
join in this nation-wide competition to turn scientific proposals for the application of genomics 
technologies in developing countries into business plans. The five best groups are invited to present their 
business plans before a professional audience at an international conference. The best group wins the 
competition's grand prize: the realisation of their business plan and a visit to the country where the project 
will be actually carried out. 
 In the programme 2008-2012, the DNA labs, www.watisgenomics and Imagine will be further 
embedded, developed and used in a number of public events that will be organised by CSG and the 
Genomics Centres. These may be the aforementioned science week but also a series of exhibitions and 
Festivals. 
Last but not least, not only the public needs to be educated and informed about the developments 
within genomics, also genomics scientists, ELSA researchers, policy-makers and other professionals 
deserve attention. Genomics develops rapidly and generates new and unforeseen applications that require 
both reflection and use by scientists and professionals. Scientists have an important role to play in public 
interaction. Not only do we need good researchers, but also experts that are able to communicate and 
interact with broader audiences and stakeholders and who are well-prepared for this challenge.  
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Empowerment of patients, consumers and citizens. 
Activity: Website for upper secondary students and general public. 
Background: The website watisgenomics.nl was launched in 2005. The 
website is an initiative of CSG together with the other Genomics Centres. It 
offers information to a broad audience, in particular to upper secondary 
students and has recently been evaluated. With 13,000 hits a month, it is 
mainly focused on upper-secondary students and this focus should be 
strengthened. The site should provide more input for assignments while 
remaining of interest for other interested publics. Deliverables: 200.000 hits 
per year; 250 new articles; 15 thematic issues; 1000 news items; embedding 
in the science centres and the Virtual Knowledge Centre Biotechnology 
(VKB); Embedding in the new curriculum of upper secondary education.  
III.2a 
Watisgenomics.nl 
Genomics Centres – Drs. Frans van Dam – 0,8 fte; 60 months 
Activity: Exploitation and development of 8 mobile DNA labs. Background: 
At the moment, five Genomics Centres have developed a Mobile DNA lab 
for secondary education. These labs have been one of the most successful 
communication activities of the Genomics Centres. Deliverables: 120.000 
school children will have used the labs; Development of three new labs 
(Ecogenomics, Proteomics and Metabolomics); Development of virtual lab; 
International programme and exchange of labs; Embedding of the labs in the 
science centres; Courses for secondary school teachers; Courses for student-
assistants; Embedding the labs, and genomics as such, in the biology 
curriculum and the new “Nature, Life and Technology” (NLT) course. 
III.2b 
DNA Mobile 
Laboratories  
CSG, CMSB, CBSG, CGC, Kluyver, NBIC, Proteomics, Ecogenomics and 
Metabolomics – 1.6 fte; 60 months 
Activity: School competition concerning genomics and developing 
countries. Background: Imagine aims to encourage scientists in applying 
their expertise to pressing problems in developing countries and to increase 
young people’s involvement in global development issues. The potential for 
interesting a large audience in beneficial applications of genomics is great 
and will be further explored and exploited. Deliverable: Links with 
developing countries; Links with valorisation programmes of participating 
centres; Media attention; Documentary on national television; Book series 
on successful projects. 
III.2c Imagine 
 
Imagine was awarded the 
Silver Hour-Glass 
Educational Prize (2006) 
and was a nominee for the 
European Commission's 
Descartes Prize for Science 
Communication ( 2007)  Genomic Centres & Kluyver Centre  
Activity: Organisation of a number of large-scale Public Events. 
Background: Large public events such as those organised in collaboration 
with Science Museum NEMO and in the Art House LUX in Nijmegen have 
attracted enthusiastic audiences. The Centres aim to establish more of these 
events in order to prompt discussion and debate and to inform citizens about 
genomics. As a start of a whole series of events, the Centres have offered the 
organisation of the Science Seek to make “DNA” the topic for next year’s 
science week (p. 29). Question: what is the effect and impact of public 
events? Background: Events will be thoroughly assessed through surveys 
and small pilots. Deliverable: Series of events; Tools for organising 
dialogue, debate and communication. 
III.2d 
Large Public Events: 
* Science week  
* Interactive Science 
Exhibition 
* Genomics Festivals  
* Radio show  
 
Genomics Centres – 1.2 fte, 60 months.  
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Activity: Permanent interactive exhibition on Forensic science at science 
museum Naturalis. Background: Forensic DNA research receives a lot of 
public attention, due to some well-known court cases and the popular TV 
series CSI. This area of genetics has been merging into daily life most 
rapidly, without much commotion or public debate. This seems to hold a 
major message: the clearer the public perceives the benefit the less debate. 
On the other hand this may also be the moment to take stock of this 
development. The information and education of the public concerning the 
actual precision in the light of advancing knowledge and technologies 
deserves serious attention. Deliverable: permanent interactive exhibition 
space on forensics and genomics (using a genomics lab as starting point). 
III.2e 
Forensic Science in 
Naturalis:  
Forensic Genetics Consortium Netherlands (FGCN)/ CSG- in collaboration with 
Naturalis Leiden – 0.2 fte; 12 months 
 
 
Education for (young) genomics scientists, ELSA researchers and professionals. 
Activity: training programme for young genomics researchers. Background: 
Young scientists, before obtaining their PhD, should be familiar with and 
aware of the societal aspects of genomics. Training should include the 
following aspects: 1) societal aspects of genomics; 2) public communication 
(including media training), 3) career perspectives (outside the lab). From 
past experiences, we know that PhD training is most successful when it is 
embedded in established training and education programmes and more or 
less “tailor-made”. While some of our Centres already have a “society-
programme” for PhD students and post-docs, others do not have such 
facilities available yet. Deliverables: Inventory of existing programmes and 
experiences; Training modules for genomics researchers.  
III.2f 
Training and capacity 
building for young 
Genomics Scientists. 
 
GeNeYous & Genomic Centres – Prof. Dr. Arend Jan Waarlo & Drs. Terry 
Vrijenhoek – 0, 6 fte; 60 months. 
Activity: interdisciplinary training modules. Background: a series of 
interdisciplinary events will be organised to bring together genomics 
scientists and ELSA researchers. Deliverables: Interdisciplinary modules for 
genomics and social scientists; Agenda for future interactions and events; 
International collaboration (for instance Marie Curie programmes) 
III.2g 
Interdisciplinary 
training modules 
 
Genomics Centres, CSG & GeNeYous – Dr. Annemiek Nelis & Drs Terry 
Vrijenhoek. 0,2 fte; 60 months 
Activity: training modules for ELSA genomics researchers. Background: 
For a sustainable knowledge network of ELSA genomics, capacity building 
is crucial. Teaching modules concerning ELSA genomics developed by 
Genomics Centres will be further developed into a coherent programme. 
Deliverables: Bachelor modules for Communication studies and 
interdisciplinary studies; Communication courses; Summer schools (e.g. 
Amsterdam, Oxford); Open days; International collaboration  
III.2h 
ELSA Education  
Genomics Centres - in collaboration with CESAGen, International School for 
Humanities & Social Science, University of Oxford.- 0,6 fte; 60 months  
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Activity & Question: (how to) design suitable educational activities for pre-
vocational schools. Background: About 60% of all secondary students 
attend a pre-vocational school. This school population is heterogeneous in 
terms of cognitive ability, learning style, ethnicity and culture. However, 
many educational professionals prefer to focus on other target groups they 
are more familiar with. As a consequence up to now little attention has been 
paid to involving pre-vocational students in the genomics information chain. 
Deliverables: Identifying ‘good practices’; Develop teaching modules for 
pre-vocational schools; Develop a hands-on lab for the science centres in the 
Netherlands. 
III.2i 
Educating Young 
people at pre-
vocational school15 
CGC - Prof. Arend Jan Waarlo – 1.0 fte; 48 months 
Activity: Developing teaching modules for genomics professionals. 
Background: Genomics is a fast developing field. Not only scientists and the 
public are in need of continuous education, also professionals lack 
knowledge of genomics that may (one day) be relevant for daily practices.  
Education modules days will be organised for oncology nurses (CGC) 
primary care workers (CMSB), (industrial) stakeholders, school teachers 
etc. Deliverables: Information days for oncology nurses; Training for school 
teachers; Personalised training modules (PIN/Accredidact) for primary 
health care workers (e.g. GP’s).  
III.2j 
Education of (future) 
Professionals  
CMSB, CGC, Kluyver Centre & CBSG. – in collaboration with professional 
organisations – total 0.6 fte ; 60 months 
 
 
 
                                                 
15 VMBO: Voortgezet Middelbaar Beroeps Onderwijs 
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Programme IV Network Activities  
Beside the three programmes, CSG also organises a number of activities that focus on the network itself 
and that aim to foster and strengthen the research community. In particular, this network will be fostered 
through the organisation of the exchange of knowledge. These activities will all be organised and 
developed by CSG itself.  
Strengthening the international ELSA genomics network 
Activity: organisation of annual international conference. Background: 
CSG, together with its sister organisation CESAGen, organises an annual 
conference on “Genomics & Society”. It has been organised four times so 
far. CSG and CESAGen take turns in organising the conference in 
Amsterdam and London. Next years conference will take place in 
Amsterdam in 2008.  
IV.a 
International 
Conference ELSA 
Genomics  
 CSG – in collaboration with CESAGen (UK)/ESRC genomics network 
Activity: acquisition of new funds. Background: The FP7 Science in Society 
programme envisions a more dynamic governance of the science and society 
relationship; a strengthening of potential and broadening of horizons with 
respect to science education; and the promotion of effective two-way 
communication channels that enable the public to engage with science and 
vice versa.16 We will use and strengthen our collaborative networks in order 
to contribute as a prominent expert centre to this process. As coordinator of 
ERASAGE we are in an excellent position to use our international contacts. 
Deliverable: Substantial portfolio of EU projects, notably in the context of 
Science in Society, but also in the Health domain, building on our activities, 
expertise and networks; Realizing the objectives of ERASAGE. 
IV.b 
EU projects 
coordinating actions 
and research 
CSG (EU Officer) - in collaboration with European partners – 0.15 fte; 60 months 
Activity: Organisation of workshops and seminars. Background: The 
Genomics Centres will continue to organise regular workshops and seminars 
on ELSA-genomics related topics. CSG will on a regular basis invite 
international guests to give lectures and presentations nation-wide for 
academics, students, policy makers and broader audiences. 
IV.c 
Workshops and 
Seminars 
CSG office & Genomics Centres – 0.1 fte; 48 months 
Activity: communication strategy. Background: CSG issues a Newsletter17 
that is distributed to a network of over 1,000 readers. CSG will continue to 
use this newsletter and other sources of communication to up-date and 
inform the international ELSA community.  
IV.d 
Newsletter & 
communication 
 CSG office - 0.1 fte; 48 months 
Activity: visiting professorship programme. Background: The Centre has 
developed a scheme to offer prominent scholars the possibility to visit the 
Centre for 3-6 months. Visiting guests are required to give a number of 
guest lectures and to be involved in research activities.  
IV.e 
Visiting Professorships  
 CSG management - 0.05 fte; 48 months 
 
                                                 
16 Science in Society Work Programme 2007, p. 4. 
17 Cf. www.society-genomics.nl 
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Deliverables 
 
Deliverables 
Publications   20 PhD Thesis’s  
 5 academic book publications 
 250 scientific articles  
 25 professional articles 
 50 articles in popular magazines, newspapers etc.  
Watisgenomics.nl  50 articles from ELSA genomics researchers for watisgenomics.nl 
 200,000 hits on www.watisgenomics.nl per year 
 250 new articles, 15 new themes & 200 news items for watisgenomics.nl 
 embedding of watisgenomics.nl in the science centers  
DNA mobile labs & 
school education  
 120,000 school children using one of the mobile DNA labs 
 development of 4 new mobile DNA-labs  
 development of a Virtual Lab and a Hand-hold lab.  
 embedding of the mobile DNA labs in the science centers, the new NTL 
curriculum and in a number of (breeding) companies.  
 A permanent exhibition on Forensic DNA in Naturalis 
 Annual school competition Imagine (producing book, press reports and 
documentary) 
 embedding of genomics in the new biology curriculum 
Teaching Modules & 
Courses for: 
 Students at pre-vocational school level 
 Bachelor & Master students 
 Professionals (oncology nurses, GPs, primary care professionals, school 
teachers) 
 PhD & Post-graduate students (genomics science and social 
science/humanities) 
Public Events   10 large national public events (science week, festivals, radio shows) 
 2 large information days for patients 
 45 local public discussions and debates.  
 10 virtual public discussions and debates  
 30 professional and public workshops and other meetings  
Policy Events   10 large policy events  
 10 policy briefs  
Academic events  5 international conferences on the Societal Aspects of genomics 
 15 visits from national and international scholars  
 15 workshops for ELSA genomics researchers 
  
  
7 Composition of the Centre and its networks 
Home Base 
In the period 2008-2012, the Centre for Society and Genomics (CSG) coordinates and develops an 
(inter)national programme for societal research and interaction. The CSG management team will be the 
coordinator for both the NGI Genomics Centres and the Dutch ELSA community. CSG is located at the 
Department for Philosophy and Science Studies of the Faculty of Science, Radboud University Nijmegen. 
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It is part of the Institute for Science, Innovation & Society (ISIS), one of six research institutes of the 
Faculty of Science. 
 
Three Networks 
CSG coordinates three different networks. Firstly, it coordinates the societal activities of the Genomics 
Centres funded by NGI (table 2). Secondly, CSG coordinates the network of ELSA researchers in the 
Netherlands: the ELSA-genomics network. This network includes both participants in the MCG 
programme of NWO and researchers from current CSG projects. Thirdly, it coordinates and builds a local 
ELSA-research community at Radboud University and a platform of local genomics researchers for 
improving visibility and outreach. Research and educational activities of the Department of Philosophy 
and Science Studies are for the larger part focussed on genomics. 
 
Centres of Excellence Innovative Clusters Technology Centres 
Centre for BioSystems Genomics 
(CBSG)  
Centre for Medical Systems Biology 
(CMSB) 
Kluyver Centre for Genomics of 
Industrial Fermentation (Kluyver 
Centre) 
Cancer Genomics Centre (CGC) 
Healthy Ageing (NCHA) 
Ecogenomics Consortium  
Forensic Genetics Consortium 
Netherlands (FGCN) 
Nutrigenomics Consortium 
Celiac Disease Consortium (CDC) 
VIRGO Consortium  
 
Netherlands Proteomics Centre (NPC)  
Netherlands Bioinformatics Centre 
(NBIC)  
Netherlands Toxicogenomics Centre 
(NTC) 
Netherlands Metabolomics Centre 
(NMC). 
 
Table 2, list of formal partners of CSG from NGI’s genomics network.  
 
With these three networks, CSG aims to involve a substantial number of key experts as well as a 
substantial number of universities. Appendix 2 maps the (university) locations of the different groups 
represented in our networks. To coordinate the three networks for societal research and societal 
interaction, CSG has appointed six principal investigators (PIs) representing six different universities 
(table 3). During the past 2,5 years, they have developed substantial research programmes in the field of 
ELSA genomics and are leading figures for each of their disciplines (STS, Philosophy, Ethics, Community 
Genetics, Science Communication and Science Education). Together with the management team they are 
responsible for defining and maintaining the synergy and focus of the research programme. Each PI is 
responsible for one of the six themes of the programme (chapter 8). Three of these six PI’s have direct 
links to one of the Genomics Centres of NGI. 
 
Prof. Dr. Martina Cornel (VUMC / CMSB)  Prof. Dr Guido de Wert (UM) 
Dr Dirk Stemerding (UT) Prof. Dr Michiel Korthals (WUR) 
Dr Patricia Osseweijer (TUD / Kluyver Centre)  Prof. Dr Arend Jan Waarlo (UU / CGC) 
Table 3: list of PI’s. See appendix 2 for CVs of each of the PI’s  
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In addition to these networks, CSG also has a number of strategic partnerships with public interest groups 
and organisations that foster and/or organise public interaction, public communication and policy 
engagements. 
Finally, CSG is committed to expanding and strengthening its international networks, both on a 
European and on a global level, through joint activities (such as EU projects, conferences, dissemination) 
and exchange (such as visiting scholars, newsletter, education). FP7 offers good prospects and 
opportunities for continuing and up-scaling our activities. Our involvement in ERASAGE and other 
European initiatives places us in a most promising position to achieve these goals. 
 
8. Management and organisation 
To fulfil our aims and ambitions and to create a sustainable knowledge network, the organisation- and 
management structure of CSG will guarantee: 
- Management of a coherent, focussed programme  
- Strong collaboration with Genomic Centres  
- Strong collaboration with ELSA researchers (CSG as platform) 
- Further development of international networks 
- Strong embedding of CSG at Radboud University  
 
The organisation of CSG is based on the three programmes described above (Genomics Applications, 
Genomics Agenda and Genomics Education and Communication), subdivided into six themes. Every 
programme is managed by a Programme Manager, and every theme by a Principal Investigator (PI). The 
core of CSG thus consists of three teams involving one programme manager and two PIs. 
Moreover, every programme combines research and interaction. All three teams have a joint 
responsibility to develop a coherent set of activities in accordance with the general programme and profile 
of CSG and the financial framework set out by the management team. While the three programme 
managers are positioned at Radboud University, the PIs are prominent ELSA experts. Besides prominent 
research groups, they represent relevant disciplines and collaborate with Genomics Centres (as was 
already outlines above). Their names and affiliations are shown below (CVs in Appendix 3).  
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CSG Organisation 
Business Programme manager Programme manager Programme manager 
director Application Genomics Agenda Education & 
  Communication 
 
Bureau Principal Investigator Principal Investigator Principal Investigator Principal Investigator Principal Investigator Principal Investigator 
Practices & Identity & Transformation 
of knowledge 
production 
Knowledge & Public 
interaction 
Education & 
Behaviour Benefits Expertise Policies 
    
 
 
Team Team Team Team Team Team 
Practices & Identity & Transformation 
of knowledge 
production 
Knowledge & Public 
interaction 
Education & 
Behaviour Benefits Expertise Policies 
    
   
Dr. Annemiek Nelis is manager of Programme 1 (Genomics applications). Prof. Dr. Hub Zwart is manager 
of Programme 2 (Genomics agenda). A programme manager for Programme 3 (Education and 
Communication) will be appointed. This will be a non-academic with a high-public profile and expertise 
in the field of education, industrial relations, arts or public debate. Together, Programme Managers and 
Principal Investigators form the Programme Committee, responsible for the annual update of the overall 
programme. 
The Programme Managers, together with the Business Director, constitute the CSG management 
team. Thus, programme managers are linking pins between the scientific and managerial level. As 
scientific director, Hub Zwart will chair the programme committee. The management team will be based 
at the RU in Nijmegen.  
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CSG Programme Committee 
Programme mgr Annemiek Nelis Hub Zwart 
Programme mgr Programme mgr Education & 
Genomics Agenda Applications Communication 
 
 
 
Cornel / VU De Wert / UM Stemerding / UT Korthals / WUR Osseweijer / TUD Waarlo / UU 
PI Practices & PI Identity & PI Transformation 
of knowledge 
production 
PI Knowledge & PI Public 
interaction 
PI Education & 
Expertise Policies Behaviour Benefits 
 
 
As general director, Annemiek Nelis is responsible for all CSG activities. She is the chair of the 
management team. Hub Zwart is scientific director and responsible for the scientific quality of the 
programme, and (as chair of the department and director of the research institute ISIS) also for the 
embedding of CSG at the Radboud University and the Faculty of Science. Business tasks (financial 
management and organisation) are the responsibility of the General Director and will be delegated to the 
business director. Managerial tasks (monitoring, planning and control) are handled by the management 
team. All members of the management team are based at Radboud University. The management team 
determines the financial framework for the programme committee. It is supported by a staff bureau for 
finances and administration. Overall communication activities (public website, corporate communication, 
etc.) are also Nijmegen-based. 
CSG Management team 
    
 Programme 
manager 
Hub Zwart Annemiek 
Nelis Business 
Director 
 
Education & 
Communication
  
 Scientific General   Director Director  
 
CSG’s international Scientific Advisory Board will assess the scientific quality and relevance of each 
research project. This committee consists of: Prof. Dr. George Gaskell (chair, London School of 
Economics), Prof. Dr. Ruth Chadwick (Cardiff, CESAGen), Prof. Dr. Herbert Gottweis (Vienna, 
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Department of Political Science) and two members yet to be appointed: a genomics expert of international 
renown and an international expert on genomics communication and/or education.  
The Foundation CSG is the legal entity under which the Centre functions. The board of the 
foundation is based in Nijmegen. The supervisory board of the Foundation consists of the following 
persons: Prof. Dr. J van Eijndhoven (Erasmus University Rotterdam), Dr E. Meijer (Unilever), Prof. Dr. 
H. Thijssen (Radboud University), Prof. Dr. R.Hoppe (Twente University), Mr. M.Buchel (science 
museum NEMO). The CSG management reports to the supervisory board twice a year.  
 
 
9. Breakdown of costs 
Budget 
The strategic plan CSGII aims at a total budget of 25 million €, 15 million € for research, 7 million € for 
societal interaction, 3 million € for organisation and management. All activities are financed on the basis 
of the NGI Strategic Plan. No matching is required. Yet, the Radboud University is strongly committed to 
CSG and will continue to support the activities of CSG. It will facilitate embedding CSG in the Radboud 
University both now and in the future and provide additional costs for the research time of the general 
director (0.4 fte), the scientific director (0.6 fte), the director communication and education (0,2) and the 
communication officer (0.2 fte). Also, the research efforts of researchers and assistant professors of the 
Department of Philosophy and Science Studies will be dedicated to genomics research (2.0 fte). The total 
matching of the RU amounts to 3.4 fte per year which is the equivalent of 410 K€ annually (2050 K€ in 
total for 5 years). Moreover, building on our results so far, substantial additional funding will be acquired 
through EU projects. This will become increasingly important. Indeed, building a solid infrastructure on 
the basis of NGI funding, resulting in a robust set of firmly embedded local and international activities and 
networks, will be of key importance for continuation of our activities after 2012. The breakdown of costs 
of the programme is presented in the following tables. 
 
Costs have been calculated on the basis of core costs + 50% per 12 months18:  
PhD students   62.5 K€  
Support staff  75 K€ 
Post-doc   100 K€ 
Lecturer   100 K€ 
Professor   150 K€ 
  
  
                                                 
18 These are the budgets that are being used by the Radboud University. For some of the projects of the Centres of Excellence, 
slightly different budgets have been used.  
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Nr Project Title  2008 2009 2010 2011 2012 Personnel 
cost 
Facilities/ 
other costs 
Total Costs fte 5 
yrs 
1.1a Evaluation of the heelprick 100 100    175 25 200 2 
1.1b Screening for Haemoglobinopathy 100 100    175 25 200 4 
1.1c Legal Framework  80 100 20   200  200 4 
1.1d Learning from the past. I  160 160 160 160 150 630 160 790 9,5 
1.1e Future testing of multifactorial diseases  50 50    100  100 1 
1.1f DNA databanks  80 120 120 80 400  400 4 
1.1g Governance of Prevention   80 120 120 80 400  400 4 
1.1h Patient participation in genomics  50 50 50 50 50 250  250 4 
1.1i Toxicogenomics: genomics based alternatives 50 50 50 50 50 250  250 4 
1.1j Viral genomics: preventive strategies  50 50 50 50 50 250  250 4 
1.1k Informing Parliamentary debate     40 40 40 20 100 120 0,2 
1.1l A conversation on Genomics    20 20 20 20 20 60 80 0,2 
           
1.2a The societal demand for new genetic tests 20 20 20 20 20 50 50 100 0,4 
1.2b The societal demand for genetic screening 20 20 20 20 20 50 50 100 0,4 
1.2c Ageing 50 50 50 50 50 200 50 250 2 
1.2d Behavioural Genomics 80 80 40   200  200 2 
1.2e Genomic Identities & human enhancement 50 50 50 50 50 250  250 4 
1.2f Individualized choice in prenatal screening? 80 80 40   200  200 2 
1.2g Estimating Risk: Ageing & Longevity 50 50 50 50 50 200 50 250 2 
1.2h Tailored intervention strategies  100 125 125 100  450  450 6 
1.2i Consumer and consumer behavior  110 100 100 100 100 500 10 510 8 
            
2.1a genomics profile: the bioinformation society 150 100 100 100 100 550  550 7 
2.1b Societal profile of ecogenomics  70 70 70 70 70 350  350 5 
2.1c Nutrigenomics practice beyond the laboratory 100 100    200  200 2 
2.1d The Changing innovation system  80 80 40   200  200 2 
2.1e Anticipatory novels as test-bed  90 90 90 90 90 450  450 6 
2.1f Future scenario's or innovation journeys  50 50 50 50 50 250  250 4 
           
2.2a Towards a fair and global-local just IPR system  50 50 50 50 50 250  250 4 
2.2b Public private partnerships 70 70 60   200  200 2 
2.2c Empowering local knowledge producers 55 50 50 50 50 240 15 255 4 
2.2d Identifying issues for the Genomics Agenda (1)   95 95 95 95 100 480   480 6 
2.2e Identifying issues for the Genomics Agenda (2) 12 12 12 12 12  60 60   
2.2f Setting the societal agenda for genomics 70 70 70 70 70 150 200 350 2 
2.2g Upstream deliberations  80 80 40   200  200 2 
            
3.1a Learning from the pas 25 25 25 25  100   100 1 
3.1b Public Voices in the life sciences. 25 25    50  50 0,5 
3.1c The DNA dialogues  50 50 50 50 50 100 150 250 1 
3.1d New Modes of Interaction  150 150 110 70 70 300 250 550 3 
3.1e Information days  50 265 50 50 265 280 400 680 3.4 
3.1f Consumer information & Communication 85 90 90 85 80 400 30 430 8 
3.1g Visions of Genomics  80 80 80 80 80 380 20 400 4,3 
3.1h Social responsibility  60 60 60 60 65 305  305 4 
3.1i Public Survey    30  30   60 60  
           
3.2a watisgenomics.nl 130 130 130 130 130 400 250 650 4 
3.2b DNA Mobile laboratories  555 420 420 420 420 865 1370 2235 8 
3.2c Imagine 50 50 50 50 50  250 250 4 
3.2d Large Public Events  150 205 285 130 100 370 500 870 6 
3.2e Forensic science in Naturalis 20 100    20 100 120 0,2 
3.2f Training and capacity building scientists 75 75 75 75 75 275 100 375 3 
3.2g Interdisciplinary training modules 50 50 50 50 50 100 150 250 1 
3.2h ELSA education  100 100 100 100 100 300 200 500 3 
3.2i Education at pre-vocational schools  75 75 75 75 80 280 100 380 4 
3.2j Education of (future) professionals  105 105 105 105 100 250 270 520 3 
            
4a International conference ELSA Genomics     40   40  80 80  
4b EU Projects coordination  15 15 15 15 15 75  75 0,75 
4c Workshop and Seminars  20 20 20 20 20 20 80 100 0,2 
4d Newsletter /communication  5 5 5 5 5 20 5 25 0,2 
4e Visiting Professorship 30 30 30 30 30 10 140 150 0,1 
4f Dissemination  20 20 20 20 20 20 80 100 0,2 
4g Publications  50 50 50 50 50   250 250  
               
5 Management  600 600 600 600 600 3000  3000  
6 Reservation               2900  
  5237 5667 4387 3912 3897 16410 5690 25000 173,15 
Table 4 Total Costs Programme 2008-20012 (K€) 
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Table 5 Total Budget per Programme (K€) 
Programme  Theme  Requested from 
NGI (k€) 
Personnel 
(k€) 
Personnel 
Fte 
Other 
(k€) 
Changing practices and 
policies 3240 2870 40,9 370 
I. Genomics applications 
Identity and Behaviour 2310 2100 26,8 210 
Transformation of knowledge 
production 2000 2000 26 0 
II. Genomics Agenda  
Knowledge & Benefits  1795 1520 20 275 
New forms of public 
interaction 2825 1915 21,8 910 
III. Education, 
Communication 
Education and Expertise  6150 2860 36,2 3290 
IV.Network   780 145 1,45 635 
Management  3000 3000   
Reservation  2900    
Totals  2500 16410 173,15 5698 
 
 
 
Partner 2008 2009 2010 2011 2012 Total 
Research 
Total 
Interaction 
Total 
CSG (RU) 
655 655 490 475 475 2750  2750 
CMSB 
580 625 295 250 150 1500 400 1900 
CGC 
260 505 305 305 505 1500 380 1880 
Kluyver  
395 385 375 375 385 1500 415 1915 
CBSG 
372 372 347 342 327 1500 260 1760 
Ageing  
100 100 100 100 100 400 100 500 
ELSA 
730 890 730 590 510 3450  3450 
Collective 989 989 989 989 989 500 4445 1084519 
Subtotal  
     13100 6000  
Totals 
7581 5121 4231 4026 4041   25.000 
Table 6 Contribution of NGI to CSG (Radboud), Genomics Centres and ELSA network.  
 
 
 
 
                                                 
19 Including management costs (3000 K€) & Reservation (2900 K€) 
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Managerial positions Name Management time Research time 
  NGI Matching Radboud University 
    Fte per year (K€) for 5 years fte (K€) 
General Director dr. A. Nelis 0,6 450 0,4 300 
Scientific Director Prof. H. Zwart  0,2 150 0,6 450 
Business Director  vacancy 1 750   
Programme manager 
Communication 
vacancy 0,2 150 0,2 150 
Financial support vacancy 0,8 300   
Communication officer dr. F. van Dam  0,6 300 0,4 200 
Office manager  M.Cantore 1 375   
Additional costs   75   
      
Principal investigators  Prof. G de Wert 0,1 75   
 Prof. M. Cornel 0,1 75   
 dr. D. Stemerding 0,1 75   
 prof. M. Korthals  0,1 75   
 prof. A. Waarlo 0,1 75   
  dr. P. Osseweijer 0,1 75   
Staff Philosophy & Science 
Studies 
   2,0 1050 
 Managerial 
capacity 5 3000 
Research 
matching  2050 
Table 7 Management Costs & Contribution Radboud University  
 
 
Societal Valorisation 
CSG first of all contributes to societal valorisation of genomics. Good governance will stimulate 
conditions for innovation and valorisation and to evidence-based policies in this area. Although the impact 
and significance of societal research and interaction for society is an important item of concern for CSG, 
impact in terms of financial benefits will be difficult to measure and define. Rather, valorisation 
(prospects, benefits, role of valorisation in government funding) is an object for research (theme 2) and in 
this way CSG can be expected to contribute to overall strategies of valorisation. It is clear that a societal 
programme is necessary to ensure or strengthen impact and benefits of genomics research and embedding 
of this research in a societally meaningful way. Therefore CSG’s activities constitute an indispensable 
component of NGI’s overall Strategic Plan, on the condition that our activities are organised in close 
interaction with the Genomics Centres, and this is what our programme aims to achieve. Finally, there is 
evidently a valorisation aspect on our objective to build a sustainable knowledge structure. Utilisation of 
CSG’s output is a relevant concern for all three programmes.  
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10. Embedding after 2012 
Science and society are changing rapidly. As a converging and enabling field, genomics is a dynamic 
research area by definition. In the coming years, genomics will disseminate to new domains and 
increasingly become embedded in various forms of knowledge production. This is already happening. 
New fields such as ecogenomics, toxicogenomics and metabolomics are becoming increasingly important. 
Our knowledge society is changing as well. There is an increasing demand for sustainable energy and new 
materials, for tailored medicines and more reliable knowledge concerning the causes of disease and the 
relationships between food, lifestyle and health. Genomics is part of this globalising world in which the 
use and exchange of information (e.g. “biobanking”) becomes increasingly important. In other words, 
genomics is here to stay, but it will migrate to novel fields and often become so firmly embedded that it no 
longer will be viewed as a separate research approach. Genomics will increasingly be used and applied to 
address emerging societal demands. This means that CSG’s mission, expertise and infrastructure will 
remain relevant beyond 2012.  
Three stages can be distinguished in societal research and interaction concerning genomics. 
During the first stage (CSG I 2004-2007) genomics was still basically a laboratory phenomenon. Societal 
research and interaction was often of an exploratory and anticipatory nature. During the coming years 
(CSG II 2008-2012), more and more genomics applications will become available, and genomics research 
will become relevant for various societal practices. In other words, genomics is rapidly migrating from the 
sphere of promises to the sphere of implementations, albeit not in a straightforward or technology-driven 
way. On the contrary, genomics applications will be adopted and adapted in a dynamic and creative 
manner by various stakeholders, and society will increasingly influence the ways in which genomics 
research will evolve. This means that, more that in the past, our research will have to be relevant for 
policy development and societal organisations. 
As for the future we expect that, after 2012, genomics research will have contributed to numerous 
research fields and societal practices so that CSG will have to broaden its scope. We will use the expertise, 
networks and infrastructures developed in order to address broader areas of concern. Or, to put it 
differently, our expertise and networks will become relevant for a much large group of stakeholders and 
for newly evolving research and societal agendas. New application-oriented initiatives have already been 
established. Top Institutes such as Pharma (TIP), Green Genetics (TTIGG), the Top Institute for Food and 
Nutrition (TIFN) and the Centre for Translational Molecular Medicine (CTMM) are examples of this 
trend. CSG’s agenda will become increasingly relevant for such initiatives.  
 After 2012, CSG will continue to exist. First of all, on the local level, the Radboud University has 
committed itself to ensure CSG’s continuity in the form of tenures for key personnel (general director, 
scientific director, communication officer and office manager). This implies that CSG’s management team 
 46
CSG Societal Research & Public Interaction 2008-2012  
will remain in place and that our three core programmes, and the six themes they encompass, will be 
further developed in the future. And indeed, we believe that after 2012, issues concerning genomics 
applications (dissemination of genomics to novel areas), the genomics agenda (emergence of new 
constellations and research fields) and genomics education and communication (for instance bèta-gamma 
interaction) will remain relevant. Moreover, on the national level, the Genomics Centres have committed 
themselves to continuing their collaboration with CSG after 2012. This means that CSG will continue to 
play a crucial role in the development of their societal activities (research and interaction). Building on 
established collaborations with Genomics Centres and the ELSA genomics network, in line with our 
programmes and themes, sufficient critical mass will have been established for extending our activities 
into the future. Yet, besides continuation, there will be new challenges as well. Instead of relying on NGI 
funding, CSG will have developed experience and robust networks for acquiring substantial additional 
funding, notably in the form of EU projects. During the past few years, we already established promising 
international networks. By further developing them through joint international activities (EU projects, 
conferences, dissemination) and by using the full potential of ERASAGE (ERANET initiative of funding 
agencies coordinated by CSG) will ensure a solid basis for international research and coordinating 
activities. Moreover, new alliances will have to be developed on the national level as well, with the Top 
Institutes mentioned above, but also with policy makers en societal partners.  
In the future, building on our networks and expertise, the CSG approach (systematically 
combining research and interaction) will be applied to other areas (bionanoscience, new materials, 
molecular medicine, etc.) in interaction with a broader range of interested partners, including more 
intensive collaborations with policy makers and governmental bodies, but also with a broader range of 
research organisation (expanding our scope beyond the genomics network). In other words, CSG will use 
the funding for developing a sustainable, prominent and visible source or expertise for conducting 
interactive research concerning the future developments and impacts of the life sciences. 
In short, after 2012, CSG will remain important as an experienced and prominent booster (both 
nationally and internationally) of academic reflection on the ways in which genomics research (or life 
science research more generally) are evolving as well as on the ways in which the process of agenda 
setting can be more strongly oriented towards emerging societal trends and needs. At the same time, CSG 
will further public visibility of this research, thereby allowing various stakeholders but also civil society at 
large to co-shape the embedding of genomics. CSG will continue to contribute to the process of 
interdisciplinary research, that is: the interaction between the sciences, social sciences and humanities. 
Finally, CSG will be well positioned (in terms of mass, focus and visibility) to play a leading role in 
further developing the emerging European and global networks for ELSA research, education and policy 
development in the life sciences in general and genomics in particular.  
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Appendix 2: Curriculum vitae of management and principal investigators 
 
Prof. Dr. H.A.E. Zwart 
 
Function: Full professor of Philosophy, Faculty of Science, Radboud University Nijmegen, Department 
of Philosophy & Science Studies (Chair), Institute for Science, Innovation & Society (Director), Centre 
for Society & Genomics (Scientific director) 
 
Address: P.O. Box 9010, 6500 GL Nijmegen, The Netherlands, zwart@society-genomics.nl 
 
Hub Zwart (1960) studied philosophy (cum laude) and psychology (cum laude) at Radboud University 
Nijmegen. He worked as research associate at the Centre for Bioethics (Maastricht, 1988-1992) and 
defended his thesis on consensus formation in a pluralistic society in 1993 (cum laude). He was appointed 
as research director of the Centre for Ethics (Nijmegen, 1992-2000) and acted as editor-in-chief of the 
Dutch Journal Tijdschrift voor Geneeskunde en Ethiek. In 2000 he became full professor of philosophy at 
the Faculty of Science. He was European lead of the EU Canada exchange program Coastal Values (1999-
2003). In 2004 he became director of the Centre for Society & Genomics, funded by the Netherlands 
Genomics Initiative and established at his department. The focus of his research is on epistemological and 
ethical issues in the life sciences: biomedicine (1988-1996), research with animals (1996-2003), 
environmental research (1998-2003) and genomics (2003-present).  
His current research concerns: the epistemological profile of genomics; philosophical implications of the 
Human Genome Project; epistemological profile of ecogenomics; challenges of macro-ethics (the ethics of 
bio-information); scientific authorship and comparative epistemology (literary imagination as a research 
tool). Hub Zwart teaches Introduction to philosophy and ethics of life sciences; Introduction to philosophy 
and ethics of science; Visible Scientists; and Science and literature. 
 
Key publications 
Zwart H (1997) What is an animal? A philosophical reflection on the possibility of a moral relationship 
with animals. Environmental Values, 6 (4), pp. 377-392. 
 
Zwart H (2000) The birth of a research animal: Ibsen’s The Wild Duck and the origin of a new animal 
science. Environmental Values, 9 (1), pp. 91-108. 
 
Zwart H (2003) Aquaphobia, tulipmania, biophilia: A moral geography of the Dutch landscape. 
Environmental Values 12 (1), pp. 107-128. 
 
Zwart H (2004) Environmental Pollution and professional responsibility. Ibsen’s A public enemy as a 
seminar on science communication and ethics. Environmental Values, 13 (3), pp. 349-372. 
 
Zwart H (2007) Genomics and self-knowledge. Implications for societal research and debate. New 
Genetics & Society, 26 (3). 
 
Memberships 
Co-editor of the journal Genomics, Society & Policy 
Editorial Board of the journal Environmental Values 
Editorial Board of the journal Tailoring Biotechnologies 
Partner in the EU FP6 Science & Society program Institutionalisation of Ethics in Science Policy 
Chair of the Dutch Association of Animal Ethics Committees 
Member of the subcommittee on ethical and societal aspects of genetic modification of COGEM 
(Netherlands Commission on Genetic Modification) 
Member scientific advisory board Ecogenomics Consortium 
Affiliated Principal Investigator Nijmegen Centre for Molecular Life Sciences (NCMLS) 
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Dr. Annemiek Nelis  
 
Function: General Director of the Centre for Society and Genomics  
 
Address: Centre for Society and Genomics, Radboud University Nijmegen. P.O. Box 9010, 6500 GL 
Nijmegen, The Netherlands; nelis@society-genomics.nl 
 
  
Annemiek Nelis (1970) is sociologist of science and technology. She wrote her Ph.D. on the development 
of clinical genetics and DNA –technology in the Netherlands and has been studying the societal aspects of 
genetics and genomics for nearly 15 years. After receiving her PhD from the University of Twente, 
Annemiek worked subsequently in Cambridge (UK) and Amsterdam (VU & UvA). During this period she 
also was responsible for the Ph.D. education programme of the research school Science, Technology and 
Modern Culture (WTMC). Since September 2004 she has been working at the Centre for Society and 
Genomics. She started at the CSG as deputy director. March 2007 she became general director of the 
CSG. Together with the scientific director, Hub Zwart, Annemiek has been responsible for the scientific 
and interactive programme of CSG. 
Annemiek is coordinator of a large ERA- network called ERASAGE. ERASAGE brings together 11 
funding organisations concerned with the Ethical, Legal and Social aspects of genomics in Europe and 
Canada.  
Her current research concerns the role of patient organisations in decision-making on genomics 
technologies; ethnographic laboratory research; and the institutional organisation and method of ELSA 
genomics.  
 
 
Key Publications  
Nelis A.P. De Vries G. & Hagendijk R. (2007) Patients as public in ethics debates: interpreting the role of 
patient’s organisations in democracy (2007) In: Atkinson, P. Glasner, P & H Greenslade, New Genetics, New 
Identities. London: Routledge, 28-43. 
 
Stemerding D., Nelis A.P. (2006), Cancer genetics and its ‘different faces of autonomy’, New Genetics 
and Society, 25 (1): pp. 1-19. 
 
Nelis A.P. De Vries, G. & Hagendijk R. (2004) ‘Stem geven’ en ‘publiek maken’. Wat 
patiëntenverenigingen ons kunnen leren over democratie. Krisis 5, 3, 25 – 40.  
 
Nelis A.P. (2000) ‘Genetics and Uncertainty’, in Brown, N. and Rappert, B. (eds.) Contested Futures, 
Asgathe Publishers, p.209-227. 
 
Nelis, A.P. (1998) DNA-diagnostiek in Nederland; Een regime-analyse van de ontwikkeling van de 
klinische genetica en DNA-diagnostische tests, 1970-1997 [Thesis]. Enschede: Twente University Press.  
 
 
Memberships  
Board Research School Science, Technology and Modern Culture WTMC (1999 – 2003) 
Member College van Advies Chronisch Zieken en Gehandicaptenraad (2001 -2004) 
Associated Fellow of the Science & Technology Studies Unit (SATSU), University of York (2000 -)  
Member of the Jury of the genomics school competition Imagine (2006 -)  
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Prof. Dr. Martina Cornel 
Function: Full professor of Community Genetics  
Address: VU Medical Centre. Postbus 7057, 1007 MB Amsterdam. M.C.Cornel@vumc.nl 
Martina Cornel, M.D, Ph.D. (1959) has been appointed as a professor of community genetics at the 
VU University Medical Center in Amsterdam in 2002. She is a physician and epidemiologist. In recent 
years she was involved in research on genetic screening criteria, a pilot on preconception screening for 
cystic fibrosis and hemoglobinopathy, research on genetic education and the international database for 
rare diseases (Orphanet). She teaches medical students and health science students in the areas of 
health promotion and large scale applications of genetics & genomics and is involved in postgraduate 
training in these areas. 
She was a member of the Health Council Committee on Neonatal Screening and is now chair of the 
program committee Neonatal Screening. In 2006/2007 she contributed to public discussions on 
screening on radio (AVRO), in Volkskrant, Bionieuws, Medisch Contact and various magazines for 
public health and ESTA (a womens magazine). She participated in debates at the Radboud University 
Nijmegen,VSOP/Erfocentrum, Genomics Momentum, CESAGEN/CSG conference, RIVM and 
VUMC.  
 
Key publications 
Achterbergh R, Lakeman P, Stemerding D, Moors EHM, Cornel MC. Implementation of 
preconceptional carrier screening for cystic fibrosis and haemoglobinopathies: A sociotechnical 
analysis. Health Policy 2007, doi:10.1016/j.healthpol.2007.02.007. 
 
Lakeman P, Henneman L, Bezemer PD, Cornel MC, ten Kate LP. Developing and optimizing a 
decisional instrument using self-reported ancestry for carrier screening in a multi-ethnic society. 
Genetics in Medicine 2006; 8:502-9. 
 
Soini S, Ibarreta D, Anastasiadou V, Aymé S, Braga S, Cornel M, Coviello DA, Evers-Kiebooms G, 
Geraedts J, Gianaroli L, Harper J, Kosztolanyi G, Lundin K, Rodrigues-Cerezo E, Sermon K, 
Sequeiros J, Tranebjaerg L, Kaariainen H. The interface between assisted reproductive technologies 
and genetics: technical, social, ethical and legal issues. Eur J Hum Genet 2006;14(5):588-645. 
 
Van Esch SCM, Cornel MC, Snoek FJ. Type 2 diabetes and inheritance: what information do diabetes 
organizations provide on the Internet? Diabet Med. 2006;23(11):1233-8. 
Baars MJH, Scherpbier AJJA, Schuwirth LW, Henneman L, Beemer FA, Cobben JM, Hennekam 
RCM, Verweij MMJJ, Cornel MC, ten Kate LP. Deficient knowledge of genetics relevant for daily 
practice among medical students nearing graduation. Genetics in Medicine 2005;7(5): 295-301. 
Memberships 
Member of the Public and Professional Policy Committee (PPPC) of the European Society for Human 
Genetics (ESHG), chair from summer 2007 onwards. 
Chair of Dutch Association for Community Genetics 
Chair of Dutch Program committee Neonatal Screening 
Associate editor Community Genetics  
Chair of working party on societal aspects of genomics, CMSB, Leiden 
Core Group member of the Center for Society and Genomics, CSG, Nijmegen. 
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Prof. Dr. Guido de Wert 
 
Function: Professor of Biomedical Ethics at the Faculty of Health, Medicine and Life Sciences, 
Maastricht University, The Netherlands.  
 
Address: Maastricht University, Faculty of Health, Medicine and Life Sciences, Dept. Health, Ethics and 
Society, P.O. Box 717, 6100 MD Maastricht, The Netherlands; g.dewert@zw.unimaas.nl 
 
The main research interest of Guido de Wert (1959) regards the ethics of genomics (including community 
genetics, clinical genetics, and behavioral genomics). In 1999, he defended his thesis Looking ahead. 
Reproductive technologies, genetics and ethics at the Erasmus University Rotterdam (cum laude).  
De Wert teaches biomedical ethics, especially the ethics of reproductive medicine and genetics/genomics 
in the curricula of both Medicine and Life Sciences at Maastricht University. Furthermore, he contributes 
to various post-academic courses in Biomedical Ethics in The Netherlands. 
He is consultant of various patient organizations, especially the VSOP (an umbrella organization). He 
regularly writes about bio-ethical (genomics-related) issues in Dutch papers. 
 
Key publications 
De Wert G, Mummery C. Human embryonic stem cells: research, ethics and policy. Human Reproduction 
2003;18: pp. 672-682. 
 
De Wert G, Meulen R ter, Mordacci R, Tallaccini M. Ethics and Genetics. A Workbook for Practitioners 
and Students. New York/Oxford: Berghahn, 2003. 
 
Harper PS, Gevers S, De Wert G, Creighton S, Bombard Y, Hayden MR. Genetic testing and 
Huntington’s disease: issues of employment. The Lancet Neurology 2004;3: pp.249-252. 
 
De Wert G. Preimplantation genetic diagnosis; the ethics of intermediate cases. Hum Reprod 2005;20: pp. 
3261-3266. 
 
Olsthoorn-Heim E, De Wert G, Winter H. Evaluatie Embryowet. Den Haag: ZonMW, 2006 (in Dutch). 
 
 
Memberships 
Guido de Wert is Crown-appointed member of the Health Council of the Netherlands, member of both the 
Council’s Standing Committee on Medical Ethics and Health Law and the Standing Committee on 
Genetics, member of the Ethics Committee of International Stem Cell Forum, and member of the Task 
Force Ethics & Law of the European Society of Human Reproduction and Embryology. 
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Dr. Dirk Stemerding 
 
Function: Assistant professor, Department of Science, Technology, Health and Policy Studies 
 
Address: School of Management and Governance, University of Twente, PO box 217, 7500 AE 
Enschede, The Netherlands, d.stemerding@utwente.nl 
 
 
Dirk Stemerding (1951) was trained in biology at the University of Groningen. He graduated at the 
University of Maastricht with a dissertation on the history of biology. General theme of his research at 
the University of Twente is the study of societal embedding of technology. In the past ten years he has 
published on a range of subjects, including (1) the introduction of new forms of genetic (DNA-) 
diagnosis in clinical genetics as well as other clinical practices (especially cancer genetics), (2) 
emerging practices of prenatal screening and related processes of social learning, (3) issues of 
government regulation in the field of the new genetics and biotechnology. He was one of the partners 
in a EU Concerted Action Programme on Genetic Services in Europe (led by prof. Rodney Harris, 
University of Manchester, 1995-1997). As principal investigator of the Dutch Centre for Society and 
Genomics he is currently involved in an interactive scenario study focussing on the dynamics and 
implications of the shift from established practices of clinical genetics to emerging practices of 
community genetics. He is also participating in a collaborative project Developing scenarios of moral 
controversies concerning new biomedical technologies (funded by the Dutch National Research 
Council) which aims at the development of a methodology assisting policy-making in this field. He 
lectures in the fields of Health Science and Technology Assessment, and has contributed to the 
Genomics and Society course of the Life Sciences master programme at the University of Nijmegen 
and the Dutch DNA-dialogues, organised by the CSG. He is member of an advisory committee of the 
Dutch Health Council which prepares a report on preconception care. 
 
Key publications 
Koch L., Stemerding D. (1994), The sociology of entrenchment: a cystic fibrosis test for everyone?, 
Social Science & Medicine 39 (9): pp.1211-1220. 
 
Stemerding D., Koch L., Bourret P. (1997), DNA-diagnosis and the emergence of cancergenetic 
services in European health care, European Journal of Human Genetics 5 (suppl. 2): 25-30. 
 
Stemerding D., Van Berkel D. (2001), Maternal serumscreening, political descision-making and social 
learning, Health Policy 56: pp.111-125. 
 
Stemerding D., Nelis A.P. (2006), Cancer genetics and its ‘different faces of autonomy’, New 
Genetics and Society, 25 (1): pp. 1-19. 
 
Achterbergh R., Lakeman Ph., Stemerding D., Moors E.H.M., Cornel M.C., Implementation of 
preconceptional carrier screening for cystic fibrosis and haemoglobinopathies: A sociotechnical 
analysis, Health Policy, 2007 (in press). 
 
Memberships 
Society for the Social Study of Science 
European Society of Science, Technology and Society 
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Prof. Dr. Michiel Korthals 
 
Function: Professor Applied Philosophy, Chair of Chairgroup Applied Philosophy, Chair 
Wageningen Ethics Centre, Wageningen University 
 
Adress: Hollandseweg 1, 6706 KN Wageningen, michiel.korthals@wur.nl 
 
Michiel Korthals (1949) studied Philosophy, Sociology, and Anthropology at the University of 
Amsterdam (UvA) and the Karl Ruprecht Universität in Heidelberg. He graduated at the UvA with a 
dissertation on the Frankfurt School. His academic interests include bioethics and ethical problems 
concerning food production and environmental issues, deliberative theories, and American 
Pragmatism. With respect to genomics he is in particular interested in deliberative theories that can 
enhance the embedding of (nutri-)genomics in dynamic and globalizing situations. He published and 
lectured on the relationship of genomics with food and agriculture. Korthals is member of various 
ethics councils of international genomics projects. As a member of the Dutch Consumentenplatform 
he advises the Dutch Government on new technologies with respect to food, agriculture, environment 
and nature. Korthals participated in the management of various GELS-genomics education programs.  
 
Key publications 
Korthals, M. (2004) Before Dinner: Philosophy and Ethics of Food, Dordrecht, Springer, p. 211. 
 
Korthals, M. (2004) Do We Need Berlin Walls or Chinese Walls between Research, Public 
Consultation, and Advice? New Public Responsibilities for Life Scientists, Journal of Academic 
Ethics, 1, 4, pp. 385-395. 
 
Keulartz, J., Korthals, M., M. Schermer & T. Swierstra (2004) ‘Ethics in a Technological Culture. A 
Programmatic Proposal for a Pragmatist Approach’, Science, Technology and Human Values, 29, 1, 
pp. 3-30. 
 
Korthals, M., & R. Bogers (eds.) (2005) Ethics for Life Sciences, Dordrecht, Springer. 
 
De Jonge B, Korthals M. (2006) Vicissitudes of Crop Benefitsharing, Development World Bioethics, 
6, 3, pp. 144-157. 
 
Memberships 
International Library of Agricultural and Food ethics (M. Korthals, Editor in Chief) 
Science Committee, Genome Canada (2002/2005) 
Centre for Society and Genomics, NWO/Radboud University, Core Group member 
Ethical Panel, EU-commission, FP6 and FP7 
NWO: Program Ethics, Research, Policy (2004-) 
NWO: Societal Responsible Innovation, Theme Committee (2006-) 
Member of Ethics Council, AQUAMAX, Sustainable Aquafeeds to Maximize the Health Benefits of 
Farmed Fish for Consumers, IP Project, EU, 6th Framework, 2006-2010;  
Member of Ethics Platform, EARNEST, Early Nutrition Programming Project, IP Project, EU, 6th 
Framework, 2006-2010; 
International collaborator of Ethical Legal and Social Issues in Nutritional Genomics, Prof. David 
Castle, University of Guelph/Ottawa & Timothy Caulfield, University of Alberta, Project AFMNET: 
Advanced Foods and Materials Network, 2006-2008; 
Member of the International Advisory Board of GE3LS Architecture, Genome Canada, Mike Burgess 
(UBC, Vancouver), 2005-2010; 
Reviewer for Genome Canada, Genome Espana, and for various journals and publishers.
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 Dr. Patricia Osseweijer 
 
Functions: Managing Director Kluyver Centre for Genomics of Industrial Fermentation; Programme 
Leader Industrial Genomics for Society. 
Address: Delft University of Technology, Department of Biotechnology, Julianalaan 67, 2628 BC 
Delft, The Netherlands; P.Osseweijer@tudelft.nl 
Patricia Osseweijer (1958) has a degree in Molecular Biology, a PhD degree in Science 
Communication at the Free University of Amsterdam (2006), and professional experience in 
curriculum development, management of fund acquisition and management of (inter)national research 
and education projects. In 1999 she was appointed Managing Director of the Department of 
Biotechnology and Executive Secretary for the Research School Biotechnological Sciences Delft 
Leiden. She initiated and presently co-chairs a new research group on ethics and society issues in 
biotechnology and has organised many international workshops and courses in this field. In 2002 
Patricia was involved in the initiation of the Kluyver Centre for Genomics of Industrial Fermentation 
and appointed Managing Director. She developed the Genomics and Society Programme and has been 
responsible, as Programme Leader, for the coordination of societal research projects in several 
universities, which were integrated in the communication strategy of the Kluyver Centre.  
 
Key publications 
Osseweijer P (2006). A short history of talking biotech (Thesis). Vrije Universiteit Amsterdam (282 
pag.) ISBN-10: 90-809691-33. 
 
Osseweijer P (2006). A new model for science communication that takes ethical considerations into 
account - The three-E model: Entertainment, Emotion and Education. Science and Engineering Ethics, 
12(4), pp. 591-593. 
 
Osseweijer P (2006). Imagine projects with a strong emotional appeal. Nature, 444(7118), 422. 
 
Osseweijer P.(1997; 1999; 2001; 2002; 2004; 2006) (Ed): Course Book Biotechnology Ethics and 
Public Perceptions of Biotechnology; Delft University of Technology & EFB Task Group on Public 
Perceptions of Biotechnology. 
 
Osseweijer P. (2004): Institutional campaigns in biotechnology in Europe: do they work? Quarck 33, 
pp.39-50. 
 
Memberships  
Redactieraad Netherlands Genomics Initiative (2003-2006) 
SBN (Stichting Biotechnologie Nederland) Board member (1999-), treasurer (2002-2007) 
NBV (Netherlands Biotechnology Society) Board member (1997-2001) 
NBV Working Group on Society Aspects of Biotechnology (1995-) 
Raad van Wetenschappelijk Directeuren Delftse Onderzoekscholen (secretaris, 1999-2004) 
Landelijke Stuurgroep Open Dag Chemie en Biotechnologie (1998-2001)  
EFB (European Federation of Biotechnology) Section on Biochemical Engineering Science (First 
Secretary, Board member)(1996-2001) 
EFB Task Group on Education (Chairman Working Group on Short Courses)(1991-) 
EFB Task Group on Public Perceptions of Biotechnology (Convenor Working Group on Research 
and Higher Education)(1993-) 
Science and Engineering Ethics. Ed. S.J. Bird and R. Spier, Springer (ISSN 1353-3452) 
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Prof. Dr. Arend Jan Waarlo 
 
Function: Professor of Genetics & Health Communication 
 
Address: Princetonplein 5, 3584 CC Utrecht, The Netherlands; A.J.Waarlo@phys.uu.nl 
 
Arend Jan Waarlo (1949) is senior lecturer in biology education and communication and holds a 
special VSOP-chair in genetics & health communication at the Freudenthal Institute for Science and 
Mathematics Education, Utrecht University. His PhD thesis was on ‘Biology teaching and health 
education’. In 1999 and 2000, he was also employed at the University for Humanistics in Utrecht. He 
has trained biology teachers, life-stance and moral education teachers, professionals in health and 
environmental education, and is currently engaged in the Utrecht Master’s Degree Programme 
‘Science Education and Communication’. He participated in various curriculum development and 
research projects. 
 
Key publications 
Waarlo, A.J. (2005) Weten en wegen. Communicatie over erfelijkheid en gezondheid. [Knowing and 
weighing. Communication about genetics and health] Utrecht: Universiteit Utrecht. (inaugural lecture)  
 
Waarlo, A.J. & Smeenk, J. (2005) Exploring genetics education in primary schools. In Ergazaki, M., 
Lewis, J. & Zogza, V. (Eds.) Trends in biology education research in the new biology era. Proceedings 
of the Vth ERIDOB Conference, Patras, Greece, 21st – 25th September 2004. Patras: Patras 
University Press. 
 
Knippels, M.C., Waarlo, A.J. & Boersma, K.Th. (2005) Design criteria for learning and teaching 
genetics. Journal of Biological Education, 39:3, pp. 108-112. 
Waarlo, A.J., Visak, T., Nieuwendijk, G.M.T., Meijman, F.J. & Brom, F.W.A. (2002) Towards 
competence-oriented genomics education and communication. Interdisciplinary scientific essay. Den 
Haag: NWO / Netherlands Genomics Initiative. 
 
Waarlo, A.J. (1999) Biology students’ forming and justifying of opinions on predictive genetic testing. 
Towards a practicable and effective teaching strategy. In Bandiera, M., Caravita, S., Torracca, E. & 
Vicentini, M. (Eds.) Research in science education in Europe. Dordrecht / Boston / London: Kluwer 
Academic Publishers, pp. 41-48. 
 
Memberships 
From 2000 to 2004 he was a member of the Academic Committee of the European Researchers in 
Didactics of Biology (ERIDOB). His current research interest is in acquiring genomics-related 
opinion-forming competence. He is manager of the CSG project ‘DNA labs for citizenship: learning 
for understanding and valuing genomics in upper-secondary education’. He collaborates with the Dutch 
Genetic Alliance VSOP since about 15 years. He regularly lectures interactively on ‘predicting and 
tinkering with DNA’ for laymen. He is a member of the editorial board of the Electronic Journal of 
Biotechnology.  
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Appendix 3: Consulted organisations  
 
Name Organisation 
  
    
Ir. M. van den Bosch Ministerie van EZ 
Dhr. J. Breekveldt Werkplaats Biopolitiek 
Mw. A.M. van Dam Nederlands Gesprek Centrum 
Drs. R. Dekker Ministerie van VROM 
Dhr. R. Gude Internationale School voor Wijsbegeerte 
Mw. Drs. J. Hensing Ministerie van OCW 
Drs. C.  Hogenhuis Stichting Oikos 
Mw. Drs. S. Homsma Nederlandse Bond voor Verzekeraars 
Ir. M. Horning Ministerie van EZ 
Prof. Dr.  M.J. van den Hoven TU Delft 
Drs. R.T.A. Janssen Nederlandse Biotechnologie Associatie NIABA 
Mw. Drs. J. Kuil Dierenbescherming 
Mw. Drs. M. van de Meent-Nutma NWO Geesteswetenschappen 
Dr. C. Oosterwijk VSOP 
Mw. G. Roebeling WECF Nederland 
Mw. Dr. S. Schalk Greenpeace Nederland 
Dr. J.T.C.M. Sprangers Ministerie van LNV 
Mr. Drs. J. Staman Rathenau Instituut 
Dr. C.M. Vos Ministerie van VWS 
Prof. Dr. P.A.Th.J. Werrij Wageningen Universiteit 
Dhr. H. van Wietmarschen Werkplaats Biopolitiek 
Drs. J.B. van den Wijngaard Ministerie van VWS 
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Appendix 4: Letters of support  
  
 
Centre for BioSystems Genomics (CBSG) – Prof. Dr. Willem Stiekema (Director) 
Centre for Medical Systems Biology (CMSB) – Prof. Dr. Gert-Jan B. van Ommen (Director) 
Kluyver Centre for Genomics of Industrial Fermentation (Kluyver Centre) – Prof. Dr. Jack Pronk 
(Scientific director), Dr. Patricia Osseweijer (Managing director) 
Cancer Genomics Centre (CGC) - Dr. J.E. Speksnijder (Managing Director) 
CSG Scientific Advisory Board – Prof. Dr. George Gaskell (Chair), Prof. Dr. Ruth Chadwick 
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Leiden, March 30 2007-03-29 
 
 
 
Centre for Society and Genomics 
Dr. A. Nelis, General Director 
Postbus 9010 
6500 GL Nijmegen 
the Netherlands 
 
 
 
Leiden, March 28th 2007  
 
 
 
Dear dr. Nelis, dear Annemiek 
 
 
We have wholeheartedly contributed to the business proposal of the Centre for Society and Genomics 
(2008-2012) for our field field of multifactorial diseases, and read with agreement the last version of it.  It 
expresses the need for societal research and public interaction concerning genomics now that 
applications increasingly affect different levels of society, identifies many issues worth adressing and 
oulines suitable trajectories for their study.  
 
In our own field this includes the realization that the players are not only the researchers and patients 
but also caretakers, insurance companies, other health professionals and a wide scala of decision 
making and funding bodies, not least NGI and its commissioning ministries, and most importantly the 
public at large.  
 
The Centre for Medical Systems Biology (CMSB) therefore fully supports the programme that the Centre 
for Society and Genomics has set out for the period 2008-2012 and is happy to be part of this 
programme. The CMSB particularly looks at bridging the gap between research developments and the 
broader use and application of results in society. Also after 2012, we see a further need for societal 
research and communication on this topic, a need that we hope to further develop and fulfill in 
collaboration with CSG. We intent to continue to bridge, together with CSG, the gap between research 
and societal use and it is the stated intention of CMSB to continue collaboration with CSG also after 
2012.  
 
 
Wishing you every success,  
 
 
 
 
Prof. dr. Gert-Jan B. van Ommen 
Director CMSB  



 
 
University Medical Centre Utrecht, Str 2.223 
Universiteitsweg 100 | 3584 CG Utrecht 
+ 31 (0)30 253 8989 / 253 3992 
a.speksnijder@umcutrecht.nl 
www.watisgenomics.nl 
 
 
 
 
Centre for Society and Genomics 
attn. dr. A. Nelis 
Postbus 9010 
6500 GL Nijmegen 
 
 April 1, 2007 
 
 
 
Dear dr. Nelis, 
 
 
Thank you for sending us the business proposal of the Centre for Society and Genomics 
(CSG) for the period 2008-2012. We agree that a strong societal programme linked to 
genomics research is of great importance, since science and society are changing rapidly. This 
is illustrated by the increased knowledge concerning the genetic changes that turn a normal 
cell into a cancer cell and realistic opportunities for a better diagnosis and treatment of this 
terrible disease that soon will be the number one killer in the Netherlands due to ageing of the 
population.  
 
The mission of the Cancer Genomics Centre (CGC) is to strengthen cancer genomics research 
in the Netherlands striving for better understanding of the cancer process so as to form a basis 
for the development of novel diagnostic and prognostic tools and the development of new 
therapeutic modalities; to strengthen the knowledge chain to commercialize results obtained 
so as to add economic value to society; to improve communication with relevant societal 
stakeholders; to establish a platform for cancer research, valorisation and communication to 
be continued after 2012. 
 
For the CGC, informing those in society who are directly affected by the developments in 
cancer genomics, e.g. cancer patients and professionals, is of utmost importance. 
Furthermore, we feel that future citizens, genomics researchers and professionals should 
receive proper education concerning genomics and its impact on society, and we therefore 
strive for a better embedding of genomics at various educational levels. In part 6 of our 
Business Plan, we have described a number of concrete outreach activities combined with 
social research that the Cancer Genomics Centre will perform in the context of CSG 
programme III: ‘Genomics Education and Communication’ in order to fulfil this ambition. 
 
 
 
 
 
The Cancer Genomics Centre supports the programme that the Centre for Society and 
Genomics had set out for the period 2008-2012. As described in our mission statement, the 
Cancer Genomics Centre will continue as a platform for cancer research, valorisation and 
communication after 2012, and within that context, will continue its collaboration with the 
Centre for Society and Genomics.  
 
 
Sincerely yours, 
 
Dr. J.E. Speksnijder 
Managing director 
Cancer Genomics Centre 
The London School of Economics and Political Science 
 
           
             The Methodology Institute 
Houghton Street 
London WC2A 2AE 
Telephone: 020 7955 7702 
Fax: 020 7955 7005 
Email:g.gaskell@lse.ac.uk 
 
  
Professor George Gaskell 
 
 
30 March 2007. 
 
Prof. Dr H.A.E. Zwart 
Dr A.P. Nelis 
Centre for Genomics and Society 
Nijmegen University 
Netherlands 
 
Re:  Centre for Society and Genomics 2008-2112: Business Plan 
 
 
Dear Hub and Annemiek 
 
I read your Business Plan with great interest.  Here you set out a strategic research programme for the Centre for 
the coming five years.  You outline an integrated, proactive and provocative programme, bringing together a wide 
range of expert contributors from the Netherlands.  While the research addresses a number of significant issues that 
will confront society as genomics develops, it does so in the context of a number of important objectives; the 
pursuit of societal embedding of genomics, practical measures for effective public engagement and education, and a 
commitment to scholarship, drawing upon the humanities and the social sciences. 
 
I am impressed by your comprehensive vision and by your success in engaging with the NGI Genomics Centres and 
other institutions and groups in the Netherlands.  I have observed similar attempts in the UK, the USA and Canada 
and come to the conclusion that the CSG is the model for others to follow. 
 
 
Yours sincerely 
 
 
 
 
 
 
 
George Gaskell BSc PhD 
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Dr A P Nelis 
Centre for Society and Genomics 
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Dear Annemiek 
 
Re: Centre for Society and Genomics 2008-12 
 
Thank you for sending me a copy of your Business plan for the period 2008-12.  I have pleasure in 
writing in support of this plan, which I am sure will ensure future work of utmost importance in the 
field.   As Director of the ESRC Centre for Economic and Social Aspects of Genomics I look forward to 
co-operating with you during this period.    
 
 With every good wish 
 
 
RUTH CHADWICK B.Phil., M.A., D.Phil. (Oxon) 
Director of CESAGen 
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